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The major histocompatability complex (MHC) encodes MHC class I 
molecules which present antigenic peptides to tumor specific CD8 T cells. 
Druggable kinases may provide the opportunity to enhance expression of 
MHC class I molecules on tumor cells. However, the regulation of MHC-I by 
kinases is largely unstudied, even though many patients with cancer are 
receiving therapeutic kinase inhibitors. The entire human kinome was 
screened using a pooled shRNA interference-based approach in a human 
mesothelioma cell line to uncover kinase regulators of MHC-I. Negative and 
positive regulators of cell surface HLA levels were discovered. A subset of 
highly scoring positive and negative kinase hits were subsequently validated 
by additional RNAi, and pharmacologic inhibitors when available. MAP2K1 
(MEK), EGFR, and RET were validated as negative regulators of MHC class I 
expression in multiple cancer types. We mapped the pathways responsible for 
increased MHC class I upon kinase inhibition. Interestingly, inhibition of the 
MAP Kinase pathway broadly influenced expression of other components of 
the antigen presentation machinery. Moreover, DDR2 and MINK1 were shown 
	to positively regulate HLA-A*02:01. This had therapeutic relevance, as shown 
with a therapeutic TCR mimic antibody to a MHC/peptide complex. Druggable 
kinases may thus serve as immediately applicable targets for modulating 
immunotherapy for many diseases. 
This is the first comprehensive analysis of kinase regulation of the 
human major histocompatibility complex class I (MHC-class I), a central 
component of the CD8 T cell-mediated response. Efficient antigen 
presentation by MHC-I molecules on cancer cells is essential for the success 
of immunotherapies, including vaccines, checkpoint blockade, adoptive T-cell 
therapy, and TCR mimic antibodies. We provide a proof of concept of two 
druggable targets, EGFR and MEK, but expect that these data can broadly 
influence translational and clinical trial design of targeted therapies combined 
with immunotherapy. 
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1 
Introduction 
 
Major Histocompatability Complex I 
 
Major histocompatibility class I molecules (MHC-I) are an essential 
target for effectors of the adaptive immune system response in infectious 
diseases, cancer, and autoimmunity. The major histocompatibility complex I is 
present in all vertebrate animals, and is expressed on the surface of all 
nucleated cells. The molecule, as the name suggests, is a polygenic 
heterodimer composed of two proteins, HLA and B2M. The first, HLA in 
humans with homologues found in vertebrates, is highly polymorphic with 
hundreds of variants. HLA is composed of three domains, the 1, 2, and 3 
chains. The 1 and 2, chains bind peptides which are presented to TCR, 
which specifically binds the peptide in complex with MHC-I(1). The second, 
B2M, is also required in the complex for stable MHC-I on the cell surface.B2M 
associates with the 3 chain and deficiency prevents any MHC-I from being on 
the surface of cells (2).  
MHC-I functions to present peptides from degraded proteins or 
defective ribosomal translation products(3–5). These peptides can be either 
foreign proteins, which are bacterial or viral in origin, or native proteins(6, 7). 
Proteins are degraded by the proteasome into smaller peptide fragments. 
These can then enter into the endoplasmic reticulum via two transporters, 
TAP1 or TAP2. Once in the endoplasmic reticulum, more processing occurs to 
generate 9-10 amino acid peptides that can bind to MHC-I(8, 9). The binding 
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between MHC-I, specifically the HLA portion, is highly sequence dependent, 
and also depends on the allele.  
The peptides in complex with MHC-I are shuttled to the cell surface, 
where a cognate TCR present on a CD8+ T-cell can bind. This binding 
between the TCR and peptide/MHC complex acts as signal 1 for the T-cell to 
elicit killing. Many secondary signals exist to either amplify or repress the T-
cell signaling which will ultimately lead to the CD8+ T-cell killing the target cell 
presenting peptide/MHC-I. 
 
Immunotherapy targeting antigens presented on MHC-I 
 
While MHC-I has long been known to play a major role in infectious 
disease due to the role it plays in presentation of viral and bacterial antigens, it 
has been more recently appreciated for the role it plays in cancer. Native 
proteins, when degraded, are presented on MHC-I. While most of these 
antigens are tolerized against centrally by the thymus, and therefore are 
unlikely to have a pre-existing active CD8+ T-cell against the peptide/MHC-I, 
some antigens have not been encountered and tolerized against and can thus 
serve as tumor antigens(10, 11). These have been shown to be bonafide 
antigens that can elicit a CD8+ mediated T-cell response, not unlike the one 
seen when a foreign antigen is presented on MHC-I(12). It has been 
appreciated that tumors, through dysregulated pathways or neo-antigens 
derived from non-synonymous mutations, can have high levels of these tumor 
antigens available for MHC-I binding(13–16).  
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An early recognized human tumor antigen, MAGE, was recognized to 
be expressed in a variety of melanomas with limited expression in normal 
tissue, with the exception of the testes(17). More importantly, anti-MAGE 
CD8+ T-cells were shown to be specific and could elicit cytolytic killing of the 
tumor cells expressing both MAGE and the HLA-A1 allele. This demonstrated 
that tumor antigens, encoded in the human genome, could serve as targets of 
T-cells and allow tumor-specific killing. The requirementsfor T-cell tumor killing 
were a sufficiently immunogenic tumor antigen, and expression of MHC-I(18). 
Further research demonstrated that certain parts of the MAGE protein were 
immunogenic, and the specific peptide could be identified and tested for CTL 
recognition.  
MAGE was not unique, and many other tumor associated antigens 
encoded in the germline were recognized over the subsequent 
years(19).Many strategies were subsequently developed aimed at targeting 
tumor antigens. Vaccine therapy is one approach, utilizing the knowledge of 
specific peptides which are presented on the MHC-I derived from tumor 
associated antigens(20). Patients have been safely vaccinated for many years 
against TAA, but little clinical efficacy has been observed. Little correlation 
between T-cell response and clinical benefit has been seen(21). Many 
theories exist why these vaccines have failed, possible due to 
immunosuppressive environment in the tumor, T-cell anergy, or a limited 
number of antigen specific T-cells that expand after vaccine administration(22, 
23).  
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Another strategy to overcome the limited clinical effect is administration 
of adoptive T-cell therapy. This strategy employs identification of a tumor 
antigen and in vitro expansion of T-cells specific for the tumor antigen, and 
then reinfusion back into the patient(24). These tumor infiltrating lymphocytes 
have demonstrated clinical efficacy in melanoma and other cancers. A much 
higher percent of tumor specific TIL was observed than what was seen with 
vaccine therapy(25). 
Other strategies utilizing TCR based therapy include using retrovirally 
encoded TCR, which can be cloned from tumor antigen reactive T-cells. This 
allows peripheral blood lymphocytes to be specifically trained to kill tumor 
specific antigens. T-cells can be harvested from patients, retrovirally 
transduced with tumor antigen specific TCR encoded retrovirus, expanded, 
and reinfused back into patients. The advantage of this approach is that it 
does not require the patient to have a pre-existing tumor reactive T-cell 
population. This approach has been used for multiple tumor antigens, 
including MART-1, WT1, GP100 tumor antigen, and others(26–28). A similar 
strategy using soluble TCR, fused to a anti CD3 specific scFv allows for bulk 
nonspecific T-cells to be redirected toward specific tumor antigen expressing 
cells (29).  
Finally, another immunotherapy strategy that depends on tumor antigen 
presentation is T-cell checkpoint blockade. In normal conditions, co-
stimulatory and inhibitory signals are expressed on cells presented antigens to 
T-cells. Expression of both co-stimulatory and immune checkpoint blockade is 
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necessary to prevent autoimmunity and protect tissue from non-specific killing 
during infection.  
One of the first described immune checkpoint receptors was CTLA4. 
Expression of CTLA4 on the T-cell can lead to decreased T-cell activation 
through inhibitory signaling and outcompeting activating CD28(30, 31). Loss of 
CTLA4 using knockout mouse models showed lethal autoimmunity(32). 
Despite the lethal autoimmunity, it was demonstrated that therapeutic 
blockade could be safely administered and showed anti-tumor activity(33). 
This paved the way for clinical trials on CTLA4 blocking antibodies ipilibumab 
and tremelimumab in melanoma. Ipilibumab fared better in trials, 
demonstrating survival benefit in metastatic melanoma, which was long term 
beyond two years (18%). Interestingly enough, doses of ipilibumab were given 
over a short course of 3 months, yet a long term benefit was observed. This 
led to FDA approval of ipilibumab(34).  
Another major checkpoint blockade therapy utilizes the PD1/PD-L1 
axis. PD-1 limits the activity of T-cells during inflammation to decrease 
autoimmunity associated with chronic T-cell activation(35). More recently, this 
has been observed as a major mechanism of immune escape by tumors co-
opting this pathway as well(36). PD1 engages with the ligands PD-L1 and PD-
L2, which are upregulated on tumor cells, to trigger inhibition of kinases 
necessary for T-cell activation(37). Mouse models demonstrated anti-tumor 
activity upon blockade of PD1 and/or PD-L1/L2(38). Interestingly, the knockout 
mouse models of PD-1 or PD-L1/L2 showed milder phenotypes than what was 
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observed when the gene encoding CTLA4 was knocked out, indicating a 
potentially better therapeutic window. Clinical trials were subsequently 
performed using human mAbs blocking PD-1 and PD-L1 in various cancers 
such as melanoma, NSCLC, and others with high response rates greater than 
20% of patients observed for melanoma and NSCLC(39).  
One advantage of targeting tumor antigens on MHC-I is that it opens an 
entirely new potential to target undruggable targets, such as transcription 
factors, or other proteins which may be difficult to inhibit with small molecule 
inhibitors. Work in our group demonstrated druggability of the oncogene WT1, 
a transcription factor essential for many leukemias and some solid tumors (40, 
41). Previous work from our lab and others identifying WT1, a tumor antigen 
with limited expression in normal tissue and overexpression in broad types of 
cancers, as an excellent target undruggable by small molecule inhibitors. It 
was ranked as the number one target by an independent panel at the NIH 
(42).  
WT1 was shown to be immunogenic by using peptide epitopes derived 
from the protein sequence that bound to HLA-A*02. In particular, one 9mer 
peptide, RMFPNAPYL, was identified to bind well and elicit CTL responses in 
vitro (43). In vivo tumor immunity in mice was observed with the WT1 peptide 
vaccine against WT1+ tumors, with minimal toxicity to normal tissue(44). This 
paved the way for human vaccination studies to be performed with WT1+ 
tumors. While immune responses were observed in patients with leukemia, 
mesothelioma, and NSCLC, little long term benefit was seen(45, 46). 
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While TCR-based therapies in their various forms provide tumor 
specificity, there are limitations to their uses due to feasibility or lack of 
predictable pharmacokinetic properties. In contrast, mAb therapies are readily 
applicable as therapeutic agents. Recently work targeting tumor antigens has 
utilized development of TCR mimic antibodies as a strategy to target tumor 
antigens presented on MHC-I (47). These TCRm antibodies target a specific 
tumor antigen in the context of HLA, similar to how a TCR on a CD8+ T-cell 
would target an antigen. The advantage of TCRm is the scalability, predictable 
pharmacokinetics, and ability to increase potency by use of BiTE or CAR-T 
cell based methods. TCRm have shown both in vitro and in vivo activity 
against human tumors expressing a variety of antigens, including WT1 (48–
50). The activity is highly dependent on the level of antigen presentation and 
expression of MHC-I, given that it interacts with this complex of peptide/MHC-
I. Work in this thesis will show the feasibility of using the TCRm ESKM as a 
mAb therapy for various cancers, and work into its development as a potent 
and specific mAb. In particular, we demonstrate the potential to combine 
ESKM with other therapies, such as TKIs in ALL or with MEKi and EGFRi in 
mesothelioma.  
 
Downregulation of MHC-I as a mechanism of immune escape 
 
In order to subvert the immune system, downregulation of MHC-I is 
often observed in broad tumor types. Given that antigens in complex with 
8 
MHC-I serve as the activation signal to T-cells, there exists a strong selective 
pressure by tumor cells to avoid the immune system by downregulation of 
these stimulatory signals, while upregulating inhibitory signals for T-cells(51–
53). In some cancers, such as Hodgkin’s lymphoma, a high rate of loss of 
MHC-I through alterations of B2M(54). Mutations have also been observed in 
the HLA-A, B, and C genes in pan-cancer analyses that may lead to ineffective 
CD8+ T cell engagement or proper antigen binding (55). Some data has 
shown that decreased MHC-I is associated with increased NK cell killing, but 
this is usually not sufficient to lead to tumor elimination (56, 57).  
While specific immunotherapies for cancer directed to MHC-I 
presentation of neoantigens, (such as checkpoint inhibition, vaccines, adoptive 
TCR cells and TCR mimic antibodies) continue to expand as effective 
therapeutic strategies, there is limited understanding of readily druggable 
pathways underlying the control of presentation of tumor antigens and MHC 
molecules. The most well understood and used pharmacologic agent for 
increasing MHC-I expression is the cytokine IFN-gamma. IFN is a type II 
interferon that is secreted by lymphocytes. IFN-gamma binds to the IFN-
gamma receptor, whereby it triggers downstream signaling via the JAK-STAT 
pathway. Many different pathways are affected by IFN-gamma, in particular 
the HLA locus, TAP1, TAP2, and B2M are induced by IFN-gamma(58–60). 
JAK phosphorylates STAT1 at Y701 and S727, which are important for 
transcriptional activation of target genes by STAT1(61). Once in the active 
form, STAT1 translocates to the nucleus whereby it can act on target genes. 
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IFN-γ induces expression of MHC-I components by targeting the conserved 
enhancer A, IFN stimulated response element, and SXY sites(62). Binding 
sites for transcription factors NF-κB and IRF are located in the enhancer A and 
ISRE sites(63, 64).In addition, components of the immunoproteasome are also 
induced by IFN-gamma, an inducible proteasome with a different preference of 
substrates based on amino acid sequence(65). All of these in concert lead to a 
drastic upregulation of MHC-I on the surface of cells.  
One would simply suggest that IFN-gamma is an ideal candidate for 
immunotherapy, and should be useful alone to increase tumor antigen 
presentation on MHC-I. Despite this, it has proven to be ineffective as a 
therapeutic agent in multiple cancer types(66). One possibility is that IFN-γ is a 
known upregulation of PD-L1 and PD-L2 on cells, and may limit T-cell 
activity(67). In addition, systemic high doses of IFN-γ required for anti-tumor 
efficacy are associated with severe toxicity(68). 
 
Rationale for current work 
With the plethora of targeted therapies and immunomodulating 
therapies present, it would be ideal to predict and study which rational 
combinations will work best. Targeting tumor antigens with immunotherapies is 
difficult because of rare cell surface presentation of individual tumor antigens. 
Hence, the regulation of this process pharmacologically might have important 
applications.  
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Kinases are involved in most aspects of cellular functions. We 
hypothesized that gene products involved in surface MHC-I expression could 
be identified by screening a custom library of shRNAs targeting the human 
kinome and using binding of specific antibodies to MHC-I as a readout. We 
surmised that by picking kinase therapies that could target oncogenic 
pathways, in addition to increasing antigen presentation in combination with an 
immunotherapy dependent on antigen presentation we could yield beneficial 
combination therapy strategies which would be difficult to discover or time 
consuming by testing in vivo combinations or clinical trials.A genome wide 
RNAi screen was performed on MHC-II surface expression by another group 
and successfully discovered novel regulators(69). Multiple kinases altering 
HLA-A expression in a human mesothelioma cell line were identified. 
Preliminary hits have been validated with other genetic means and 
pharmacologically. Several have been confirmed in other cancer cell lines. 
Previously described and novel gene products were discovered. One of the 
validated kinases was MAP2K1, also known as MEK. This kinase acts as a 
negative regulator of surface HLA-A and thus, inhibition led to increased 
surface expression of HLA-A. We were able to phenocopy the effect of the 
RNAi against MEK using a specific MEK inhibitor. The addition of a MEK 
inhibitor increased the cytotoxic efficacy of a monoclonal antibody against the 
MHC on the human mesothelioma cell line in vitro. Utilizing loss and gain of 
function screens, the discovery of regulators of MHC-I may have broad 
implications for pharmacologic intervention in multiple diseases in which 
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pathophysiology or therapy is dependent on MHC and antigen presentation. 
This includes TCR mimic antibody therapies, infectious diseases, vaccine 
therapy, TCR engineered T cell therapy, bone marrow transplantation, donor 
leukocyte infusions, and autoimmune disease. 
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CHAPTER I: UTILIZING POOLED shRNA SCREENS TO DISCOVER 
NOVEL REGULATORS OF SURFACE MHC-I EXPRESSION 
 
INTRODUCTION 
 
The use of RNA interference (RNAi) for loss of function experiments is 
powerful and reliable technique to demonstrate the involvement of a gene in a 
pathway. In particular, use of shRNA has allowed for sustained knockdown 
and observation of phenotype. RNAi works by targeting the mRNA of a gene 
by using complementary RNA to yield a hybrid double stranded RNA 
molecule. The target gene mRNA is destroyed by the host cell RNA induced 
silencing complex (RISC)(70). This technique has been validated as a rapid 
and effective way of performing loss of function screens(71).  
The advantage of using shRNA for silencing genes is that a shRNA 
hairpin can be designed to knock down a given gene and then can be stably 
incorporated into the genome using either retroviral or lentiviral methods. This 
allows for cells to be transduced with a given shRNA construct and selected 
for cells that have stable knock down of a given gene for evaluation of 
phenotypic differences. We employed the use of a pooled shRNA screen, 
whereby a population of cells is transduced with a library of shRNA targeting 
hundreds of genes. Gene products causing an increase or decrease in surface 
HLA-A can then be selected using fluorescence activated cell sorting for cells 
with high or low surface HLA-A using an HLA-A specific, fluorophore tagged 
mAb. Once the cells are isolated, gDNA can be extracted from cells and then 
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a PCR can be performed for the shRNA barcode present in the cells. The PCR 
product is then subjected to massively paralleled sequencing, where the 
abundance and identity of each shRNA for a given population is determined.  
 We decided to target the human kinome, which represents a set of 
genes involved in many different regulation pathways, has many tools to 
evaluate the state of a given pathway using western blot techniques, and is 
readily druggable with many small molecule inhibitors available for use(72, 
73). The mir30 based shRNA platform was utilized for creation of a kinome 
library. The mir30 based shRNA has been utilized before for pooled shRNA 
screens to yield druggable targets of leukemia (74). We utilized the TRMPV 
shRNA construct, which allows for tetracycline inducible knockdown, coupled 
with the dsRed fluorophore to track shRNA expression(75). The construct also 
includes the Venus fluorophore and NeoR cassette for selection of cells which 
were successfully transduced (Figure 1.1). We applied this system to screen 
for regulators of surface HLA-A in the JMN human mesothelioma cell line, 
stably expressing the rt-TA3 gene.  
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Figure1.1. A TRMPV inducible shRNA retroviral vector was used for 
transducing JMN (HLA-A*02:01 positive human mesothelioma line). TRE is 
the Tet responsive element, which drives expression of the fluorophore dsRed 
and the shRNA hairpin. The constitutive PGK promoter drives the Venus 
fluorophore along with Neomycin resistance cassette. 
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MATERIALS AND METHODS 
 
Cell lines and culture conditions: After informed consent on Memorial Sloan-
Kettering Cancer Center (MSK) Institutional Review Board–approved 
protocols, PBMCs from HLA-typed healthy donors and patients were obtained 
by Ficoll density centrifugation. The sources for obtaining human 
mesothelioma cell lines are described previously(50). Cell lines were 
maintained in RPMI supplemented with 10% FBS and 2 mM L-glutamine 
unless otherwise mentioned. HEK293T were grown in Dulbecco’s modified 
media with 10% FBS and 2 mM L-glutamine. Cells were checked regularly for 
mycoplasma. 
 
ADCC: The HLA-A*02:01 positive mesothelioma cell line JMN transduced with 
either a control shRenilla (shRen) construct or shHLA-A constructwere used in 
the ADCC assay as the targets. Cells were stably selected using 1 mg ml-1 
neomycin for 7 days. Once selected, the shRNA were induced with 2 ug/ml 
doxycycline for 96 h. ADCC was then performed. Antibodies ESKMor its 
isotype control hIgG1 at 3 ug/ml were incubated with target cells and fresh 
healthy donor PBMCs at different effector/target ratios for 6 hours, RPMI 
supplemented with 10% FBS. The supernatant was harvested, and the 
cytotoxicity was measured by a 51Cr release assay (Perkin Elmer). 
Retroviral transduction of vectors: JMN mesothelioma cell line was initially 
transduced with a vector containing the mouse ecotropic receptor, along with 
rt-TA3 and PuroR gene. Cells were selected with 5 ug/ml puromycin for 5 
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days. Retrovirus was generated from ecoptropic HEK293T (ATCC Manasses, 
VA USA) packaging cells by transfecting the cells with TRMPV vectors. Viral 
supernatant was then used to transduce JMN, and cells were selected for 7-10 
d with 1 mg/ml G418 (Life Technologies)  
Flow cytometry studies: Cells were induced with 2 ug/ml doxycycle for 
knockdown of target gene for 96 h. Cells were then analyzed by western blot 
of flow cytometry for HLA-A expression. BB7.2 was used for flow cytometry 
studies for surface HLA-A02 (Abcam). Western blot for HLA-A was performed 
with HLA-A specific goat polyclonal sc-23446 (Santa Cruz Biotechnology). 
Pooled RNAi screening 
A custom shRNA library targeting the full complement of 526 human kinases 
was designed using miR30-adapted DSIR predictions refined with ―sensor‖ 
rules (six shRNAs per gene) and constructed by PCR-cloning a pool of 
oligonucleotides synthesized on 12k customized arrays (Agilent Technologies 
and CustomArray) as previously described (Supplementary Table 1)(75). The 
list of genes was obtained from KinBase Database 
(http://kinase.com/human/kinome/) and was manually curated. After sequence 
verification, 3156 shRNAs (5-6 per gene) were combined with positive control 
HLA-A - and negative-control Renilla targeting shRNAs at equal 
concentrations in one pool. JMN mesothelioma cells stably expressing the Tet-
On rt-TA3 gene were used. This pool was subcloned into the TRMPV-Neo 
vector and transduced in triplicates into Tet-on JMN mesothelioma cancer 
cells using conditions that predominantly lead to a single retroviral integration 
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and represent each shRNA in a calculated number of at least 1,000 cells. 
(Figure 1.1) Transduced cells were selected for 6 days using 1 mg ml−1 G418 
(Invitrogen); at each passage more than 30 million cells were maintained to 
preserve library representation throughout the experiment. After induction, T0 
samples were obtained (~30 million cells per replicate (n = 3)) and cells were 
subsequently cultured in the presence of 2 μg ml−1 doxycycline to induce 
shRNA expression. After four days (Tf), about three million shRNA-expressing 
(dsRed+/Venus+) cells were sorted for each replicate using a FACSAriaII (BD 
Biosciences). DAPI negative, dsRed+/Venus+ cells were sorted by FACS into 
three populations of BB7 low, BB7 middle, and BB7 high binding (Figure 1). 
Genomic DNA from Tf samples was isolated by two rounds of phenol 
extraction using PhaseLock tubes (5prime) followed by isopropanol 
precipitation. Deep-sequencing template libraries were generated by PCR 
amplification of shRNA guide strands as previously described(75). Libraries 
were analyzed on an Illumina Genome Analyzer at a final concentration of 8 
pM; 50 nucleotides of the guide strand were sequenced using a custom primer 
(miR30EcoRISeq, TAGCCCCTTGAATTCCGAGGCAGTAGGCA). Hits with 
lower than 100 reads from the Illumina HiSeq were eliminated because they 
were not above background levels.  
 
Relative representations of each individual shRNA were determined and 
compared in each given sorted population. We separated hits phenotypically 
into negative regulators (the population one standard deviation below the 
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mean fluorescence intensity) or positive regulators (the population one 
standard deviation above the mean fluorescence intensity) of HLA-A*02:01.  
The ratio of the shRNA ranking between the high and low population was 
compared, with a high ratio indicating a putative negative regulator of surface 
HLA-A*02:01. The scoring criteria for a gene being a negative regulator of 
HLA-A*02:01 was based on having 2 or more shRNA constructs score in the 
top 5% for fold difference in relative representation between BB7 high 
population and BB7 low population, with other constructs scoring within 1 SD 
of the mean fold change. The gene products with at least two shRNA 
sequences in the top 5% ratio were selected for further validation by other 
methods. The same discovery pipeline was used for identifying positive 
regulators of HLA-A*02:01. 
For validation, the LT3GEPIR shRNA vector was used(76). Cells were 
transduced and selected with puromycin, then induced with 2 ug/ml 
doxycycline for 96 h before evaluating levels of either BB7, W6/32 or ESK, by 
flow cytometry. 
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RESULTS 
 
The human mesothelioma cell line was profiled using the IMPACT platform for 
any mutations or copy number changes in known oncogenes and tumor 
suppressors, in addition to components of MHC-I. No mutation or loss/gain of 
copy number was observed in HLA-A or B2M (Table 1.1 and 1.2) 
Table 1.1. MSK Memorial Hospital IMPACT genomic sequencing data for the 
JMN human mesothelioma cell line. Non-synonymous mutations in JMN using 
the IMPACT-410 platform. 
Gene Protein Type 
Allele 
freq Copy # 
TP53 G245S Missense 1 Diploid 
BRCA2 E2258K Missense 0.65 Diploid 
NF2 D511Afs*2 Frameshift 1 Diploid 
ZFHX3 R3381_Q3387del Deletion 0.12 Diploid 
ARID1B P450dup Insertion 0.58 Diploid 
ARID2 Y92Vfs*19 Frameshift 0.93 Diploid 
ATM C117Y Missense 0.21 Diploid 
EGFR K728N Missense 0.16 Diploid 
EPHA7 R529* Nonsense 0.28 Diploid 
ERBB3 H1085L Missense 0.61 Diploid 
ERCC3 E48D Missense 1 Diploid 
FANCA H1417D Missense 0.63 Diploid 
FLT3 L689* Frameshift 0.53 Diploid 
GRIN2A V967L Missense 1 Diploid 
KDM5C K363N Missense 0.32 Diploid 
NSD1 V1394I Missense 0.24 Diploid 
PALB2 P864S Missense 1 Diploid 
PBRM1 R365C Missense 1 Diploid 
POLD1 Q411H Missense 0.25 Diploid 
SPEN S263F Missense 0.23 Diploid 
TERT Promoter 5'Flank 0.99 Diploid 
AR G473dup Insertion 0.11 Diploid 
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Table 1.2. Copy number alterations using the IMPACT-410 platform in JMN. 
 
Gene CNA Cytoband 
CDKN2B DeepDel 9p21 
CDKN2AP16INK4A DeepDel 9p21 
CDKN2AP14ARF DeepDel 9p21 
 
 
Knockdown of HLA-A*02:01 by use of an shRNA to this gene product in the 
TRMPV vector was tested as a positive control and caused strong knockdown 
by both western blot analysis and flow cytometry (Figure 1.2AB). This was 
also confirmed to decrease killing of ESKM in an in vitro ADCC assay (Figure 
1.2C).  
 
Figure 1.2. Knockdown of HLA-A with TRMPV shRNA construct. (A) Western 
blot showing knockdown of HLA-A using TRMPV retroviral system with a 
positive control  shRNA to HLA-A02. The shRen is a negative control shRNA 
designed against the Renilla gene (B) Flow cytometry data showing 
knockdown of HLA-A using TRMPV retroviral system using a HLA-A specifc 
mAb (C) Knockdown of HLA-A causes resistance to antibody dependent 
cellular cytotoxicity by the ESK-M mAb. JMN transduced with either control 
shRen or shHLA-A and induced for 96 h was used for in vitro ADCC assay. 
Isotype or ESK-M was used as described in material and methods. 
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These data validated that if a phenotypic difference upon knockdown of HLA-A 
could be observed by flow cytometry based methods, that other gene products 
could be discovered in a similar manner to regulate surface HLA-A.  
The JMN cell line was screened as described in the methods for shRNA 
against genes acting as negative or positive regulators of surface HLA-A. Cell 
surface HLA-A was detected by flow cytometry with the HLA-A*02:01 specific 
antibody BB7.2 and fluorescence activated cell sorting was used to sort 
populations based on HLA expression (illustrated as in Figure 1.3A). 
Compared to control shRen dsRed+ cells, the positive control shHLA-A 
showed an enrichment in the HLA-A low population of >8 fold. This similar 
strategy was applied to shRNA kinome transduced cells, which were sorted by 
HLA-A expression using FACS, and then gDNA was isolated from the HLA-A 
low and HLA-A high populations. The gDNA was sequenced using next 
generation Illumina Hiseq for the shRNA barcode, which gave the identity and 
relative abundance of the shRNA in each population. The top 5 hits for 
negative and positive regulation of HLA-A are shown(Table 1.3). 
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Figure 1.3. Screen for regulators of surface HLA-A. A. Schematic depicting 
outline for screen. B. Flow cytometry data for JMN cells transduced with 
various TRMPV vectors and induced for 96 h with doxycycline. Flow cytometry 
was performed for dsRed+ (TRMPV expressing) and HLA-A expression. 
 
 
 
 
 
 
 
 
23 
Table 1.3. Top 5 negative regulatory and top 5 positive regulatory kinase 
genes that were hits from the screen for regulating surface HLA-A expression. 
Bold genes have been validated. The percentile ranking of the top 5% of 
shRNA constructs for each gene listed is shown out of 3168 constructs tested. 
 
Genes GeneID Percentile Rank of top 
shRNA 
Validated 
GRK7 
131890  
99.8%, 98.7% 
 
Yes 
MAP2K1 5604  
99.7%, 98.1%, 95.1%  
 
Yes 
EGFR 1956  
99.5%, 95.3% 
 
Yes 
RET 5979  
99.3%, 95.8% 
 
Yes 
BRSK1 
84446  
99.3%, 97.3% 
 
Yes 
DAPK3 
1613  
0.22%, 1.1% 
 
No 
DDR2 4921  
0.28%, 2.8%  
 
Yes 
CDK7 1022  
0.41%, 3.3%  
 
Yes 
MINK1 
50488  
0.47%, 2.1% 
 
Yes 
MAPK3 5595  
0.51%, 4.9%  
 
No 
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The relative representation of the MAP2K1 and EGFR shRNA constructs that 
were present in the shRNA library showed an enrichment in the population of 
sorted cells with high levels of HLA-A02 (Figure 1.4). 
 
Figure 1.4. Waterfall plot showing distribution of shRNA constructs against 
MAP2K1 and EGFR as log fold difference between BB7 high sorted population 
and BB7 low sorted population. 
  
25 
Validation was performed for the hits using the LT3GEPIR shRNA construct, 
which allows for an all in one inducible shRNA knockdown of the target gene. 
Data are shown for the validation of MAP2K1 and EGFR in the JMN human 
mesothelioma cell line. Validation was performed on an additional 
mesothelioma cell line, Meso34, and other mesothelioma cell lines which are 
HLA-A02 as well. The validation data confirmed that MAP2K1, also known as 
MEK, negatively regulates HLA-A, and inhibition leads to increased surface 
HLA-A and also HLA-ABC. 
 
Figure 1.5. A. shRNA knockdown of MAP2K1 and EGFR in JMN cells 
validates them as a negative regulator of surface HLA-A. BB7.2 is a mAb 
specific for HLA-A02. shRNA against Renilla was used as a negative control, 
while an shRNA against HLA-A was used as a positive control. Validation was 
also shown for the Meso34 and Meso56 cell line. Student’s t-test was done to 
compare each shRNA gene knockdown MFI to the shRen control. (*≤0.05, 
**≤0.01, ***≤0.001, ****≤0.0001) B. shRNA knockdown of MAP2K1 and EGFR 
in JMN cells shows increased pan surface MHC-I (HLA-A, HLA-B, HLA-C). 
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As a proof of concept, two positive regulators of surface HLA-A in JMN were 
chosen, DDR2 and MINK1, to demonstrate the ability of the screen to also 
detect positive regulators. Knockdown of DDR2 and MINK1 led to decreased 
surface HLA-A in JMN, and was validated in other cell lines as well. 
 
Figure 1.6.DDR2 and MINK1 acts as positive regulators of surface HLA-A. A. 
Waterfall plot showing fold difference between BB7 high and low sorted 
population and distribution of shRNA constructs against DDR2. B. Waterfall 
plot showing fold difference between BB7 high and low sorted population and 
distribution of shRNA constructs against MINK1. C. DDR2 and MINK1 
knockdown decreases surface HLA-A expression in JMN. Cells were 
transfected with siRNA against either a scrambled siRNA, an siRNA against 
HLA-A, or an siRNA against DDR2 or MINK1. After 96 hours, flow cytometry 
was performed as previously described. Statistical significance was compared 
to scrambled siRNA using unpaired student T-test on triplicate samples. 
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DISCUSSION 
 
The validation of MAP2K1 and EGFR as regulators of surface HLA-A 
and also MHC-I using shRNA mediated knockdown of both genes allowed for 
further investigation into the pathways governing surface MHC-I regulation and 
whether they could be manipulated by specific inhibitors. Activation of kinase 
signaling is a common occurrence in cancers, and many mutations present in 
cancer activate kinase signaling (77, 78). The validated targets which regulate 
MHC-I in mesothelioma, and also validated in other cell lines provide an 
interesting opportunity to target a pathway not only essential for proliferation of 
tumor cells, but also to increase immunogenicity of tumor cells as well, 
providing fertile ground for combination drug strategies.  
Two of the identified regulators of MHC-I, EGFR and MAP2K1 or 
MEK1, both signal in the mitogen activated kinase pathway (79)(MAPK). The 
MAPK pathway is involved in cellular proliferation, differentiation, and 
transformation, and is highly conserved throughout eukaryotes. The MAPK 
pathway consists of extracellular growth factor regulated kinases (ERK), or 
stress regulated kinases. ERK1/2 is generally regulated by receptor tyrosine 
kinase stimulation, whereas the ERK5, c-Jun kinase JNK, and p38 kinases are 
regulated by stress response and growth factor stimulation (78).  
The ERK1/2 MAPK pathway is involved in signaling when upstream cell 
surface receptor tyrosine kinases, such as EGFR, bind their respective growth 
factor, such as EGF. This causes the receptor to signal downstream to 
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cytoplasmic Ras, a guanine nucleotide binding protein(80). Ras then signals 
downstream to Raf, a serine/threonine kinase in the MAPK signaling cascade. 
Raf then signals to MEK, another serine/threonine kinase (81). MEK will then 
signal downstream to ERK1/2, which has numerous substrates such as 
transcription factors, and other kinases.  
EGFR and MEK both signal to the MAPK pathway whereby active 
signaling through the MAPK pathway leads to down regulation of MHC-I. 
Knockdown of kinases in the MAPK pathway at the level of EGFR or MEK. 
Given that both EGFR and MEK have specific small molecule inhibitors which 
can be used to inhibit their kinase activity, we decided to investigate 
pharmacologic inhibition as a means of up regulation MHC-I. 
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Chapter 2: The MAPK pathway regulates MHC-I and antigen presentation 
in cancer cells 
 
INTRODUCTION 
 
Targeted therapy for treatment of cancer has expanded largely since it 
was first demonstrated to be effective for treatment of acute promyelocytic 
leukemia(82). Targeted therapy is based on looking for aberrant pathways 
activated in tumor cells which are absent or minimally present in normal tissue. 
Characterization of the molecular pathways cancer is dependent on has led to 
numerous FDA approved therapies that can now be utilized for targeting 
specific pathways activated in cancer.  
After discovering the pathways underlying neoplasia and oncogenesis, 
kinases were shown to play crucial roles in sustained signaling necessary for 
transformation. Examples of kinase pathways contributing to oncogenesis 
include the MAPK pathway, which integrates growth signaling necessary for 
sustained proliferation and avoidance of apoptosis, or the PI3K pathway which 
is necessary for protein synthesis, metabolism, survival, and transcription of 
genes. Experiments showed that cancer cells were addicted to signaling 
through these pathways, which led to the development of small molecule 
inhibitors of kinases within oncogenic pathways.  
One of the most successful early examples of this was the use of 
imatinib, a kinase inhibitor of Abl in BCR-Abl translocated chronic 
myelogenous leukemia. Since the translocation is only present in transformed 
leukemia cells, and the leukemia is dependent on signaling through BCR-Abl 
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for growth and proliferation, this was an attractive and specific therapeutic 
target(83). After discovering a potent and specific BCR-Abl inhibitor which 
demonstrated in vitro efficacy against CML, clinical trials in humans showed 
similar promising data, with most patients having complete responses to 
imatinib as a single agent(84).  
These data provided the ground work for targeting kinases with 
aberrant signaling derived from mutations, translocations, fusion proteins, or 
amplifications of the kinase gene. Sequencing of large cohorts of patient 
derived tumors validated that many mutations are present in kinases, such as 
melanoma where up to 70% have BRAF mutations, or pancreatic 
adenocarcinoma where 95% have KRAS mutations(85, 86). Many of these 
pathways were necessary for oncogenic transformation and maintenance of 
the tumor growth, proliferation, metastasis, angiogenesis, and many other 
hallmarks of cancer. 
 The MAPK pathway had been shown to be essential in tumor growth 
and proliferation in many solid tumors. As such, inhibiting kinases that feed 
into the MAPK pathway has been demonstrated to be a viable strategy for 
targeted therapy in cancer. One example is in melanoma, where mutations in 
the kinase BRAF V600E, present in up to 40% of melanomas, have been 
targeted using a BRAF V600E specific inhibitor vemurafinib or dabrafenib(87, 
88). This has been demonstrated in vitro, and in vivo. These tumors are highly 
dependent on signaling downstream of BRAF to MEK, and ERK for sustained 
growth and proliferation. More recently, work has shown that BRAF mutant 
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melanomas are exquisitely sensitive to MEK inhibition. Despite MEK being a 
common component in other tissues requires MAPK pathway signaling, BRAF 
mutant melanomas are much more sensitive to MEKi given their dependence 
on MAPK (89).  
 This work has validated that MAPK inhibition is useful in cancer therapy 
for targeting growth and proliferation. One understudied consequence of 
MAPK inhibition has been the immunologic effect of kinase inhibition. More 
specifically, our unbiased search led us to discover two key components of the 
MAPK pathway, EGFR and MEK, to regulate surface levels of MHC-I and 
antigen presentation. We decided to use specific small molecule inhibitors to 
further investigate the pathway of MAPK inhibition of surface MHC-I and how 
this regulation could be manipulated. Inhibition of MAPK signaling may serve 
as a useful therapeutic strategy not only for slowing tumor growth but also 
increasing immunogenicity of tumors.  
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MATERIALS AND METHODS 
Cell lines and culture conditions: After informed consent on Memorial Sloan-
Kettering Cancer Center (MSK) Institutional Review Board–approved 
protocols, PBMCs from HLA-typed healthy donors and patients were obtained 
by Ficoll density centrifugation. The sources for obtaining human 
mesothelioma cell lines are described previously (50). SKMEL5, PC9, and 
UACC257 were obtained from ATCC (Manasses, VA USA). The NSCLC cell 
lines were obtained from the Scott Lowe laboratory. TPC1 cell line was a kind 
gift from the James Fagin lab. Cell lines were maintained in RPMI 
supplemented with 10% FBS and 2 mM L-glutamine unless otherwise 
mentioned. HEK293T were grown in Dulbecco’s modified media with 10% 
FBS and 2 mM L-glutamine. Cells were checked regularly for mycoplasma. 
 
Small molecule inhibitor studies: Compounds were obtained from 
SelleckChem (Houston, TX USA). Drugs were used at sub-cytostatic doses by 
titration using the Cell Titer Glo assay (Promega). All drugs were used in vitro 
at indicated doses in 1% DMSO. Experiments were performed at least twice 
with similar results, and data shown are representative.  
Flow cytometric studies: Cell lines were seeded in triplicate in a 6-well tissue 
culture plate at a density of 1E5 cells/well, and allowed to adhere overnight. 
The next day, cells were treated with either vehicle control (0.1% DMSO) or 
inhibitor at indicated concentrations. Cells were then isolated at 72 hours after 
inhibitor treatment, and washed with PBS. Cells were subsequently stained 
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with BB7.2 (HLA-A02 specific mAb) or W6/32 (HLA-ABC specific mAb). Cells 
were stained with propidium iodide for viability. Cells were analyzed on BD 
Accuri C6 flow cytometer.  
Western blot analysis: Protein lysate was isolated from cultured cells using 
RIPA buffer with protease inhibitor (50mM Tris  pH 8, 150 mM NaCl, 
0.5% sodium deoxycholate, 1%  NP-40). Protein quantification was performed 
using DC Lowry assay. Antibodies for pERK(#4370), ERK1/2 (#9102), 
pEGFR, EGFR (#4267), GAPDH, and B2M were obtained from Cell Signaling 
Technologies. Antibodies for HLA-A were obtained from Santa Cruz 
Technology.  
Treatment with EGF ligand: Recombinant EGF was obtained from Life 
Technologies and cells were treated with 100 ng/ml EGF for 72 h before flow 
cytometric analysis of surface HLA-A (BB7.2) and surface HLA-ABC (W6/32) 
was performed.  
Overexpression of mutant EGFR and NRAS: The pBABE retroviral vector 
encoding either EGFR harboring the L858R mutation was used to stably 
transduce H1299 cell line using HEK293T/Amphoteric cells and were selected 
in 2.5 ug/ml puromycin for 5 days. EGFR L858R was a gift from Matthew 
Meyerson (Addgene plasmid # 11012).  
For overexpression of NRAS the pBABE NRAS Q61K plasmid was used to 
transduce H827 cells similar to described above, and selected in 2 ug/ml 
puromycin. pBabe N-Ras 61K was a gift from Channing Der (Addgene plasmid 
# 12543). 
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Transgenic EGFR L858R mouse model: FVB CC10-rtTA/EGFR-L858R mice 
were obtained as a kind gift from the Harold Varmus lab. Mice were bred in 
accordance with MSKCC institutional review board under protocol 96-11-044. 
Mice used for the experiment were heterozygous for CC10-rtTA and EGFR-
L858R as detected by quantitative PCR genotyping. At 4-6 weeks of age, mice 
were put on doxycycline via food pellets (625 mg/kg) (Harlan-Teklad) for >6 
weeks. Mice were imaged by anesthetizing under 2% isoflurane and lung field 
images were acquired on Bruker 4.7T Biospec scanner (Bruker Biospin Inc.) 
MRI in the Small animal imaging core at MSKCC. Images were analyzed with 
Osirix Imaging Software (Geneva, Switzerland). Once confirmed to have 
reticulonodular appearances and consolidations by axial and coronal MR 
images, consistent with previous data published on the transgenic mice (90). 
 Mice were sacrificed once confirmed to have lung tumors (non induced 
control mice were also used, which genotypically were identical but did not 
receive dox diet). The lungs were isolated and treated with Collagenase IV in 
HBSS with Ca2+ and Mg2+ for 1 h 37ºC. Cells were then collected, blocked with 
mouse FcR block (Miltenyi), counted, and stained with mouse CD45 (30-F11 
Biolegend), human EGFR(AY13 clone Biolegend), and mouse H2-kq (KH114 
clone Abcam) antibodies. Flow cytometry analysis was performed on Fortessa 
(BD Biosciences).  
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RESULTS 
MAPK pathway regulation of MHC-I 
 
EGFR an MEK both have numerous specific small molecule inhibitors, with 
some being FDA approved for use in various cancers(91, 92). We 
phenocopied the inhibition of shRNA mediated knockdown of EGFR and MEK 
with the small molecule inhibitors trametinib and erlotinib in a panel of 
mesothelioma, NSCLC, melanoma, colorectal, pancreatic, and thyroid cell 
lines. Interestingly, the JMN mesothelioma and PC9 NSCLC showed up 
regulation of surface HLA-A when treated with the EGFR inhibitor afatanib, 
while all had some degree of sensitivity to the MEKi trametinib (Figure 2.1A). 
Of note, many cell lines had known driver mutations of the MAPK pathway, 
such as SKMEL5 and UACC257 melanoma lines, which have BRAF V600E 
mutations, or SW480 colorectal carcinoma and CFPAC pancreatic 
adenocarcinoma cell lines which had KRAS G12V mutations. The TPC 
papillary thyroid cancer had the RET/PTC1 rearrangement. We further showed 
that this effect was valid not only for surface HLA-A, but more broadly on pan 
MHC-I using W6/32, a mAb specific for HLA-ABC in a selected number of cell 
lines (Figure 2.1B) 
 Not only did we demonstrate that EGFRi and MEKi leads to increased 
surface HLA-A, but we also used TCR mimic antibodies which bind to 9-10 
amino acid epitopes derived from intracellular proteins that are presented on 
HLA-A02. We chose two TCR mimics established in the lab, ESKM and 
PRAME, which bind to peptides derived from the oncoproteins WT1 and 
36 
PRAME respectively. Using these TCRm antibodies, we demonstrated 
increased presentation of WT1 and PRAME derived peptide on JMN, Meso34, 
TPC1, and SKMEL5 (Figure 2.1C). Strong concordance was observed with 
the up regulation of HLA-A and the up regulation of TCRm binding.  
 
 
Figure 2.1. Use of selective EGFRi and  MEKi, increases cell surface HLA-A 
expression and tumor antigen presentation A. MEK inhibition and EGFR 
inhibition for 72 h with indicated inhibitors increases HLA-A (BB7 binding) by 
flow cytometry in JMN, Meso34, PC-9, UACC257, SK-MEL-5, SW480, and 
TPC1 cell lines. 1% DMSO was used as a vehicle control.B. MEKi with 
trametinib shows increased pan surface HLA-ABC using W6/32 by flow 
cytometry. Experimental setup similar to 2.1AC. Binding of TCRm antibodies 
to peptide /MHC epitopes. In blue use of ESK antibody to a peptide derived 
from the oncoprotein WT1 that is presented on HLA-A0201. Binding increases 
after inhibition of EGFR and MEK for 72 h in JMN, Meso34, and TPC1. In red 
PRAME is a TCRm antibody against an epitope of PRAME tumor antigen 
presented on HLA-A0201 on SKMEL5. Experimental setup was similar to A. 
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 We next wanted to explore how the MAPK pathway controlled surface 
HLA-A and MHC-I expression. While inhibition on the MAPK pathway either at 
the level of EGFR or MEK lead to increased surface HLA-A and MHC-I, we 
wanted to see if stimulating the pathway would lead to decreased HLA-A and 
MHC-I. We exposed JMN to EGF, in order to further stimulate the EGFR. A 
decrease on surface HLA-A and MHC-I was observed, consistent with higher 
MAPK activity leading to lower MHC-I (Figure 2.2).  
 
Figure 2.2 Treatment of JMN with 10 nM EGF for 72 h, causing activation of 
the downstream MAPK pathway, leads to decreased surface HLA-A and total 
HLA-ABC. 
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In order to further evaluate the effects of EGFRi and MEKi on surface 
MHC-I, we turned to a panel of well genotypically and phenotypically defined 
NSCLC cell lines. H827 contains the activating EGFR ELREA746 deletion, 
H1975 contains a combined EGFR L858R and gatekeeper T790M mutation, 
rendering it resistance to first generation TKI such as erlotinib and gefitinib. 
H1299 contains an activating NRAS Q61K mutation, and is insensitive to 
EGFRi. A549 contains an activating KRAS G12S mutation, also rendering it 
insensitive to EGFRi. The up regulation of MHC-I was dependent on the 
response downstream of EGFR for the two sensitive cell lines, as measured 
by pEGFR and pERK, in H827 and H1975. H1975 was resistant to the effects 
of erlotinib, a first generation TKI which resistance has been demonstrated 
before due to the gatekeeper T790M mutation(93), but sensitive to newer 
second and third generation TKI(94). H1299 and A549 were resistant to 
EGFRi mediated up regulation of MHC-I, and did not show a decrease in 
pERK on treatment with erlotinib or afatanib but did respond to MEKi with 
trametinib (Figure 2.3). These results show that genotype of the tumors can 
predict response to MHC-I up regulation based on MAPK inhibition. 
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Figure 2.3A. UseofEGFRierlotinibandafatanib, 
alongwithMEKitrametinibonH827 (EGFRE746del-A750 mutation), H1975 
(L858R/T790M), H1299 (EGFRwt, NRASQ61K), andA549 
(EGFRwt/KRASG12S) toaltersurfaceHLA-ABClevels. Student’st-
testwasdonetocompareeachtreatmenttovehiclecontrol. 
*Pvaluesannotatedasinfigure 2.1. B. 
WesternblotanalysisshowinglevelofinhibitionoftheMAPkinasepathwayonpanelo
fNSCLCcelllinesusing 1% DMSO (D), 100 nMerlotinib (E), 100 nMafatanib (A), 
or 500 nMtrametinib (T). 
  
One interesting result was that while MEKi and EGFRi both led to a 
similar level of suppression of pERK activity, EGFRi had a statistically 
significant higher up regulation of MHC-I than MEKi in EGFR mutant cell lines. 
This led us to determine whether EGFR was capable of suppressing MHC-I in 
the presence of an already active MAPK pathway due to a downstream 
mutation. H1299 has an NRAS Q61K mutation, causes signaling downstream 
to RAF, MEK, and ERK. We ectopically expressed the constitutively active 
EGFR L858R mutation in H1299, leading to a phenotypically EGFR 
mutant/NRAS mutant cell line. When comparing the cell line to the vector 
alone, EGFR L858R coexpression led to further suppression of MHC-I, despite 
similar levels of pERK in both lines (Figure 2.4). It is possible that there are 
A) B)
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non MAPK functions of EGFR signaling responsible for the suppression of 
surface MHC-I.  
 
Figure 2.4. Surface MHC-I can be down regulated by constitutively active 
EGFR in the context downstream RAS mutations. A. H1299 cells were 
transduced with retroviral vectors expressing EGFR L858R. Western blot 
analysis of vector transduced versus EGFR L858R transduced cell lysate 
shows activated pEGFR signaling. B.  H1299 with either vector alone or EGFR 
L858R expressing were analyzed for surface pan HLA-ABC using W6/32. 
 
We further demonstrated in the H827 EGFRm cell line that EGFRi alone was 
able to increase MHC-I as much as when combined with MEKi, whereas the 
single agent MEKi alone did not cause as large of an increase (Figure 2.4A). 
Both MEKi, EGFRi, and the combination caused similar levels of inhibition of 
pERK. The H827 cell line was transduced with either vector alone or NRAS 
A) B)
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Q61K, which has been demonstrated to be a mechanism of resistance of 
EGFRi (95). Despite resistance to MAPK suppression in NRAS Q61K 
expressing cells with EGFRi, as seen by pERK output, a change was 
observed in surface MHC-I expression, though lower than with MEKi 
(Figure2.5B). 
 
Figure 2.5.A. EGFR inhibition upregulates surface HLA-ABC greater than 
MEKi despite equivalent levels of inhibition of pERK output. B. EGFRi up-
regulates MHC-I despite downstream mutations causing constitutive MAPK 
activation. The NRAS Q61K mutation was introduced into H827 and cells were 
treated with EGFRi or MEKi as done in 2.4A 
  
A) B)
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We next explored mechanistically how surface MHC-I is regulated upon 
inhibition of the MAPK pathway. Treatment with EGFRi and MEKi in a panel of 
cell lines lead to increased transcript levels of the mRNA for HLA-A, along with 
B2M. We also assessed increase in components of the antigen presentation 
machinery, such as TAP1 and TAP2. We also observed increases in 
transcripts for these genes as well (Figure 2.6).  
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Figure 2.6. MEK and EGFR inhibition for 48 h leads to increased levels of 
HLA-A, along with TAP1, TAP2, and B2M in JMN, Meso34, SK-MEL-5 and 
UACC257, H827, and PC9 cell lines 
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In order to demonstrate that the effect of up regulation of MHC-I was a 
dose dependent process, we treated JMN and SKMEL5 cell lines with 
increasing amounts of MEKi trametinib, and assessed pERK levels by western 
blot and surface HLA-A by flow cytometry. Interestingly, SKMEL5 was 
sensitive to the effects of trametinib at lower doses than JMN (Figure 2.7). 
 
Figure 2.7. Dose dependent increase in surface HLA-A with increasing MEKi 
in JMN and SKMEL5. Cells were analyzed by flow cytometry at 72 h 
 
Sensitivity to MEKi based on genotype has been previously reported that 
melanomas with BRAF V600E mutations are much more sensitive to MEKi 
than wild type BRAF cell lines, which is the case for JMN and Meso34 (89). 
This was likely due to feedback inhibition, as the JMN and Meso34 cell lines 
pERK levels were sensitive at an earlier timepoint of 1 h treatment with 
trametinib (Figure 2.8A), whereas later timepoints at 72 h showed rebounding 
of pERK (Figure 2.8B). In comparison, the melanoma BRAF V600E mutant 
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cell lines remained sensitive at t=72 h to MEKi with trametinib at low levels 
(Figure 2.7C). 
 
Figure 2.8. Titration of trametinib to determine optimal inhibition of MEK using 
pERK as a marker of inhibition. A. JMN and Meso34 were incubated with 
increasing doses of trametinib for 1 h and analyzed by western blot for pERK 
and ERK. B. Cells were incubated with trametinib for 72 h. C. SKMEL5 and 
UACC257 were analyzed by western blot at 72 h for pERK and ERK. 
 
We further demonstrated that not only did transcript levels of HLA-A and B2M 
increase, but also protein levels in mesothelioma cell lines upon MEKi. We 
also confirmed a similar dose dependent pattern with EGFRi (Figure 2.9).  
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Figure 2.9. MEK inhibition or EGFR inhibition leads to increasing levels of 
HLA-A and B2M protein. Cells were treated with indicating amounts of 
trametinib (MEKi) or erlotinib (EGFRi) for 72 hours and specific antibodies 
against indicated proteins were blotted 
 
One striking finding was how in some cases, transcript levels and protein 
levels of B2M increased drastically, while levels of HLA-A did not increase by 
as much or at all. We hypothesized that increased B2M may be sufficient to 
drive increased surface MHC-I, as it is a necessary protein that 
heterodimerizes with HLA to remain as a stable complex on the surface of 
cells. We overexpressed B2M and showed that this was sufficient to drive 
increased surface HLA-A and pan HLA-ABC (Figure 2.10).  
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Figure 2.10. Overexpression of B2M leads to increased surface HLA-A and 
HLA-ABC. Western blot showing increased protein levels of B2M 
 
We next demonstrated that upon MEKi, activity on the promoters of HLA-A 
and B2M increases using a luciferase promoter assay, which the HLA-A and 
B2M promoters were cloned upstream of the gaussian luciferase gene. IFN-
gamma is a known positive regulator of HLA-A and B2M, acting via the JAK-
STAT pathway, and lead to an increase in activity on both the HLA-A and B2M 
promoters as well (Figure 2.11)(96–99). 
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Figure 2.11. Treatment of JMN with MEKi trametinib for 72 h leads to 
increased activity on the HLA-A and B2M promoter. The HLA-A and B2M 
promoter was cloned upstream of the Gaussian Luciferase gene. SEAP under 
the CMV promoter was used as a normalization factor. 
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The HLA-A and B2M gene expression is regulated by multiple regulatory 
domains in the promoter region, including the ISRE site, E box, and NF-B 
sites. Knockdown of the STAT1, STAT3, and RelA (component of NF-B 
complex) were performed on JMN cells, along with treatment with MEKi. 
STAT1 knockdown had the largest effect in blunting up-regulation of surface 
HLA-A after MEKi, suggesting a role for STAT1 in response to MEKi (Figure 
2.12). 
 
Figure 2.12. Knockdown of STAT1, on JMN cells treated with MEKi 
demonstrates role in mediating surface HLA-A up-regulation. JMN cells were 
transfected with siRNA against genes shown and treated with either DMSO or 
1 uM trametinib 24 h after siRNA transfection, then assayed by flow cytometry 
for surface HLA-A expression 72 h after treatment. 
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We next wanted to see whether activation of the MAPK pathway would lead to 
decreased levels of MHC-I and antigen presentation components in vivo. 
Microarray profiling of the lung bearing tumors from transgenic EGFR L858R, 
which activates the MAPK pathway, compared to normal lungs, demonstrated 
suppression of mouse MHC-I and antigen presentation components H2-KD, 
and B2M, thereby confirming the effects of this pathway in vivo (100)(Figure 
2.12). 
 
Figure 2.13. Unsupervised hierarchical clustering microarray expression 
profiling analysis of lung tumors from CC10/L858R mice with EGFR L858R 
tumor bearing lungs (right side, black) or normal lungs (left side, green) 
focusing on H2-KD, B2M, TAP1, TAP2, PD-L1(PDCD1), and PD1 (CD274) 
gene expression. 
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Up-regulation of PD-1 and PD-L1 markers in the tumors was also observed as 
previously published (101). Expression of EGFR L858R in the transgenic mice 
with treatment on doxycycline for >6 weeks was demonstrated by increased 
binding of a human EGFR specific fluorescently labeled mAb (Figure 2.13A). 
Mice were confirmed to have development of lung adenocarcinoma by MR, 
with development of a reticulonodular infiltrate in the lung consist with previous 
publications(90). The CD45-/hEGFR+ population in the lung in the EGFR 
L858R expressing mice demonstrated decreased binding of a MHC-I specific 
mAb by flow cytometry, when compared to a wild type mouse which did not 
express the EGFR L858R mutation. (Figure 2.14B).  
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Figure 2.14.A.  FlowcytometrydataofFVBCC10-
rtTA/TetOEGFRL858Rexpressingmice. Micewereinducedwithdoxycyclinefor>6 
weeksbeforesacrificed (mice E-G). Control mice were kept on normal diet, but 
genotypically identical (A-D). 
LungswereisolatedandstainedwithmarkersforCD45 (panleukocyte), hEGFR, 
andH2-kq (MHC-I). B. TheCD45- lungpopulationwasstainedwithmouseH2-
kqspecificmAb. CD45-/hEGR- populationshowshigherMHC-
IexpressionthanCD45-/hEGFR+ population. Representative MRI images of 
mouse lungs are shown for two samples.  
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Improving immunotherapy by increasing MHC-I expression and antigen 
presentation using MEKi 
 
We finally wanted to demonstrate that regulation MHC-I and antigen 
presentation with kinase inhibitors had a beneficial effect to immunotherapy for 
cancer. We utilized two TCR mimic mAbs, ESKM and PR-20. ESKM is a 
TCRm directed towards an epitope from WT1, an oncoprotein present in 
numerous hematopoietic and solid tumors (21, 50, 102, 103). PR-20 is a 
TCRm targeted an epitope derived from the PRAME oncoprotein also present 
in various hematopoietic and solid tumors (104, 105). We demonstrated that in 
two HLA-A02+/WT1+ cell lines, combination therapy with the MEKi trametinib 
along with ESKM resulted in superior killing in an ADCC assay, when 
compared to vehicle or single agent alone (Figure 2.15AB). This also worked 
for the PR-20 antibody against an HLA-A02+/PRAME+ melanoma cell line 
(Figure 2.15C). 
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Figure 2.15.Improving immunotherapy efficacy by up-regulating cell surface 
MHC-IA. Antibody dependent cellular cytotoxicity assay was performed on 
JMN human mesothelioma cell line. Cells were incubated for 72 h with either 
vehicle control or trametinib and subsequently exposed to either isotype 
antibody or ESKM in ADCC assay B. ADCC assay on Meso34 (human 
mesothelioma). Experimental setup was similar to 2.14A. C. ADCC assay on 
SKMEL5 (human melanoma) using TCRm mAb PRAME against the PRAME 
epitope, experimental setup similar to 2.14A. 
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Another model that we investigated was using T-cell based killing in 
combination with MEKi. The B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J mice 
express TCR specific for the gp100 pmel tumor antigen(20). We harvested T-
cells from the spleen of a pmel transgenic mouse and used these cells as 
effectors. After treating the pmel+ B16F10 murine melanoma with either 
vehicle or 1 uM trametinib, we exposed them to pmel specific T-cells in an 
overnight killing assay, then performed a clonogenic assay to assess 
killing(106). Finally, we also demonstrated increased killing by specific T cells 
following use of MEKi to up-regulate MHC-I. The pmel-1 gp100 specific mouse 
T cells were more effective at killing of the gp100 positive target B16F10 
melanoma cells following trametinib treatment, which correlated with pERK 
inhibition and MHC-I up-regulation (Figure 2.16ABC) 
 
Figure 2.16. B16F10 cells were exposed to pmel-1 (gp100) specific TCR T-
cells for 24 h, then killing was assessed using a clonogenic assay described 
previously.A. B16F10 cells were exposed to pmel-1 (gp100) specific TCR T-
cells for 24 h, then killing was assessed using a clonogenic assay described 
previously (50). B. B16F10 pERK levels, as measured by pERK intracellular 
staining, in cells treated with vehicle or 1 uM trametinib. C. B16F10 MHC-I 
expression assessed by flow cytometry after treatment with 1 uM trametinib for 
72 h. 
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DISCUSSION 
 
 
Immunotherapy of cancer is emerging as a successful and important 
component of treatment. MHC molecules presenting antigens are the target of 
multiple therapeutic strategies that involve vaccines, T cells or TCR’s, TCR 
mimic antibodies, or T cell checkpoint blockade. The latter, a highly effective 
recent example in cancer therapy, appears to require presentation of 
neoantigens on MHC-I on the surface of cancer cells (107–109). Many 
immunotherapies have focused on intrinsic effector cell mechanisms, such as 
the T-cells, for modulating the immune response, but not the target of the 
immune attack. The ability to regulate such responses by affecting target cells 
could have an important impact on both disease and therapy. We propose that 
kinases are a readily druggable pathway that might be used in conjunction 
with immunotherapy to enhance efficacy. The beneficial effect of the 
combination of immunotherapy with kinase inhibition was shown in mouse 
models of combined PD-1/PD-L1 blockade with MEKi (110). A second model 
of adoptive T-cell therapy in combination with MEKi in BRAF mutant murine 
melanoma has demonstrated superiority to single agent alone (111). Our work 
has provided a mechanistic understanding of these combination therapies 
leading to up-regulated MHC-I and antigen presentation, essential for the 
adaptive immune response. Indeed, many of the patients treated currently with 
immunotherapies also receive kinase inhibitor therapies as distinct treatments. 
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The loss and gain of function screen described here allowed unbiased 
interrogation of the currently annotated human kinases for their regulation of 
cell surface MHC-I. We then explored mechanistically how such kinase 
regulators could be inhibited for altering surface expression of MHC-I, as a 
way of validating the screen, understanding the process, and also for 
extending the findings to functional modulation of a model immunotherapy 
proof of concept that directly depends on MHC-I presentation. In this case, we 
were able to specifically isolate the MHC as the sole target of the therapy by 
use of therapeutic TCR mimic antibodies directed to antigens presented by 
MHC.   
 
This study also provides a proof of concept for use of a flow cytometry based 
loss of function pooled shRNA screen in an application to the study of 
regulation of other cell surface molecules, and potentially intracellular antigens 
as well. This technique will allow many laboratories without robotics and high 
throughput flow cytometry equipment to investigate pathways that can be 
easily perturbed with loss of function RNAi screens or other techniques such 
as CRISPR loss of function.  
 
While we demonstrate the effect of the MAPK pathway on MHC-I in vivo, the 
study of certain kinases, such as MEK, to increase MHC-I surface expression 
and antigen presentation is complex because T-cells and NK cells also rely on 
similar kinase signaling pathways for activation. More work needs to be done 
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to determine optimal pathways or schedules or doses to target MHC in tumor 
cells specifically, while sparing signaling pathways of the effector cells (112). 
Some work has suggested conflicting effects of MEKi on T-cell effector 
function, and may be dependent on the tumor model evaluated (113, 114). 
Optimal dosing schedules will be needed in models in vivo and in humans to 
show that use of kinase inhibition to regulate immunotherapy has therapeutic 
benefits while sparing immune effector cells of the detrimental effects. These 
investigations will be complicated by the effects of some of the drugs on the T 
cell effectors themselves. 
 
The data provide a mechanistic explanation of how MHC-I is regulated by the 
MAPK pathway. MHC-I mRNA expression is regulated through upstream 
enhancer elements, with involvement of the NF-B transcription factor (96, 
115). MHC-I is also induced by TNF, IL-1, interferon beta, and interferon 
gamma, which up-regulates HLA-A via the JAK/STAT pathway (99, 116). The 
CIITA transcription factor can also act on MHC-I gene expression (97). 
Interferon gamma has been shown to increase MHC-I and antigen 
presentation, but thus far has had limited applications for this use (117). MEK 
has been proposed by others to be a regulator of MHC-I expression. EGFR 
inhibition can augment MHC-I and MHC-II expression in keratinocytes (118). 
MEK is a negative regulator of HLA-A*02:01 in esophageal and gastric cancer 
(119). We validated these targets in the screen as an important negative 
regulator of MHC-I and discovered a mechanistic role of the MAP kinase 
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pathway in regulating surface levels of MHC-I. Interestingly, activating EGFR 
mutations may contribute to immune escape due to PD-L1 expression. Down-
regulation of MHC-I, which was observed from our study, may also contribute 
to this finding (101). Our data also suggest that using combination therapy of 
MAP kinase inhibition can be powerful not only as a direct cancer therapy to 
prevent growth, but also indirectly to promote immunotherapy. 
 
For autoimmune disease, the HLA genes have been shown to be a risk factor 
for diseases such as ankolysing spondylitis, multiple sclerosis, and other 
diseases (120–122). In addition to up-regulation by certain kinases, we were 
also able to show down-regulation of MHC-I through new kinase targets. 
These targets are not currently addressed by immunosuppressive therapies, 
which inhibit the effector arm of the immune response with concomitant 
toxicity. These new targets warrant further development of specific inhibitors 
and mouse models to elucidate the utility of using kinases to alter autoimmune 
disease, also beyond the scope of this report.  
 
A requirement of many immunotherapies therapies is the availability of 
recognizable antigens that are presented on MHC-I. Tumors can down 
regulate MHC-I to avoid immune system detection of the rare neo-antigens 
created in tumors by mutations, in addition to up-regulation of inhibitory 
receptors. By modulating the levels of these limited antigens, improved clinical 
efficacy could be seen with certain immunotherapies in conjunction with 
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current FDA approved small molecules targeting EGFR and MEK. We also 
discovered that the inhibition of the kinase pathways caused a more general 
up-regulation of the antigen presentation machinery, including Tap 
(responsible for transporting peptides) and B2M (responsible for stabilizing 
MHC). Many of the recently approved immunotherapies, such as CTLA-4 
blockade and PD-1 blockade, release the T-cell inhibition promoted by target 
tumor cells. These immunotherapies provide a promising approach to 
addressing multiple malignancies, and by rationally combining with targeted 
small molecule inhibitors, this approach may allow for novel synergistic 
treatment strategies to be developed.  
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CHAPTER 3: STRUCTURE OF A THERAPEUTIC TCR MIMIC ANTIBODY 
WITH TARGET PREDICTS PHARMACOGENETICS 1,2 
 
INTRODUCTION 
 
Antibodies are ideal drugs for cancer therapy, given their ability to 
specifically target antigens, predictable pharmacokinetics, high affinity binding, 
track record of success in the clinic, and ease of production. Antibody targeted 
therapies have been highly successful in selectively killing cancer cells by 
various mechanisms with reduced adverse effects. More than a dozen cancer 
therapeutic antibodies are used clinically (123). Antibody therapies target 
extracellular proteins, and a major unmet challenge has been targeting 
intracellular cancer specific proteins, which are more common and often more 
specific to the cancer. Also, many intracellular targets are considered 
undruggable, including many transcription factors which are known to be 
involved in oncogenesis (124). One strategy to target intracellular antigens is 
to direct antibodies to peptides derived from oncoproteins that are displayed 
on the cell surface by major histocompatibility complex (MHC) class I 
receptors, which may have limited expression in normal tissue (48, 125).  
The Wilms Tumor 1 protein (WT1) is overexpressed in most 
hematological and solid tumor cancers (40, 126), and peptides derived from 
WT1 are displayed by HLA receptors as 9-10 amino acid T-cell epitopes for 
presentation to the TCR (43, 127). We used ESK1 as a model TCRm, which 
                                                 
1Modified from Ataie N, Xiang J, Cheng N, Brea EJet al.J Mol Bio. 2014 
2Some experiments were designed and conducted by or in collaboration with 
Niloufar Ataie and J. Xiang as noted in the text.  
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we have demonstrated has in vitro and in vivo activity in solid and 
hematopoetic tumors. ESK1 binds the WT1 derived peptide epitope 
RMFPNAPYL (RMF)/HLA-A*02:01 complex with 0.2 nM affinity and triggers 
WT1-specific cancer cell death (128–130).  
X-ray crystal structures of TCR and TCRm have been used in the past 
to yield novel insight into binding orientations and allow for comparison with 
each other. TCR in complex with peptide/MHC-I have very little variability in 
binding orientation, with most binding in similar locations (131, 132).  TCR 
mimics have demonstrated diverse binding orientations (133, 134).  
Insight into binding will also allow for prediction of off-targets of ESK1. 
Given the ability for potent antibody therapy, TCR based therapy, CAR-T cell 
and bispecific enganging antibodies to destroy targets, a thorough 
examination of off targets is also necessary. Cases of off target reactions have 
been seen with TCR therapy against MAGE antigen, which cross reacted with 
an epitope from titin and caused cardiovascular toxicity in a patient(135).  
In collaboration with N. Ataie, J. Xiang, H. Ng, and C. Lui, we solved the 
crystal structure of the RMF/HLA-A*02:01/ESK1 (Fab) complex to 3.05 Å. The 
ESK1 variable domains bind the HLA and peptide in a different mode than 
TCRs. ESK1 CDR loops contact regions of HLA that TCRs typically do not 
reach. Our structure and binding studies also show that RMF acts as an 
electrostatic key in mediating ESK1 specificity and activity with Arg1 playing a 
central role. RMF Pro4 also contributes to ESK1 binding.   
65 
The rest of the binding interface is limited to interactions between ESK1 
and a region on the HLA receptor that is conserved between subtypes, 
suggesting that binding is compatible with other common HLA-A*02 subtypes, 
which we experimentally confirmed. While HLA-A*02:01 is the most common 
HLA-A*02 subtype in the United States and Europe, other subtypes bearing 
different peptide and TCR binding specificities are found across different 
ethnic groups worldwide (136, 137). Unlike TCR, which are restricted to 
subtype and would cause allograft reactions, this unique ability of ESK1 
potentially broadens the target patient populations for this drug beyond the 
HLA-A*02:01 subtype found predominantly in Caucasians to multiple other 
ethnic groups. The crystal structure allowed additional predictions of possible 
cross-reactive human self-peptides, which were confirmed in vitro. In this way, 
we use structural data as a tool for pre-clinical antibody pharmacogenetics and 
toxicology. 
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MATERIALS AND METHODS 
 
ESK1 design, construction, purification 
The antibody ESK1 was prepared as described previously (128). Briefly, ESK1 
was derived from the top clone selected from the Eureka Therapeutics human 
single-chain variable fragment (scFv) phage library with specific binding for the 
RMF/HLA-A*02:01 complex. The full-length human IgG1 form of ESK1 
antibody was produced in the Chinese Hamster Ovary (CHO) cell line. ESK1 
antibody was affinity purified by Protein A chromatograph with an AKTA FPLC 
system. 
 
ESK1 flow cytometry binding assay to RMF peptides 
T2 cells, a TAP1/2 deficient HLA-A*02 expressing cell line that does not 
present endogenous peptides, were used for pulsing peptides. T2 cells were 
purchased from ATCC and cultured in RPMI with 10% FBS. Peptides were 
purchased from Genemed Synthesis (San Antonio, TX USA) with >90% purity.  
Peptides were resuspended to 20 mg/ml in DMSO and diluted to working 
stocks in PBS. T2 cells, at 1x106 cells/ml, were pulsed with peptides at various 
concentrations overnight in RPMI with 10% dialyzed FBS and 10 ug/ml β2-
microglobulin. T2 cells were incubated with peptide overnight at 37ºC with 5% 
CO2. Cells were then spun down, washed with PBS, and blocked in human 
FcR block for 15 minutes on ice. T2 cells were then stained with ESK1 labeled 
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with APC at 3 ug/ml final antibody for 45 minutes on ice. Cells were then spun 
down and resuspended in FACS buffer and run on FACS Calibur.  
 
Off target binding of ESK1 
Protein BLAST from NCBI, along with analysis using NetMHC 3.0(138) for 
peptides with a binding of <500 nM to HLA*A0201 was used to determine 
novel off targets of ESK1. The search criteria used for the protein BLAST 
were: RMFPXXXXL, RMFPXXXXV, RMFPXXXXI, RLFPXXXXL, 
RLPFXXXXV, RLFPXXXXI. Peptides were pulsed on T2 cells, as previously 
described, at various concentrations, and binding of ESK1 was measured by 
flow cytometry.  
 
HLA subtype binding assays 
Binding affinity was determined by measuring surface plasmon resonance on 
a Biacore X100. In brief, 50 µg/mL of modified streptavidin was immobilized 
onto a Sensor Chip CAP by flowing the Biotin CAPture Reagent through the 
flow cells at 2 µL/min for 5 minutes. 10 ug/mL biotinylated MHC complex 
carrying the RMFPNAPYL peptide was loaded onto the flow cell at a rate of 30 
µL/min for 3 minutes. Following the standard protocol for single-cycle kinetics, 
a series of injection of ESK1 were performed at 0.313, 0.625, 1.25, 2.5, and 5 
µg/mL, with each step consisting of a 3 minute injection at 30 µL/min and 3 
minute disassociation. Afterwards, the surface was regenerated for 2 minutes 
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with a solution consisting of 75% v/v 8M guanidine-HCl and 25% v/v 1M 
NaOH. Kinetic constants were derived by global fitting to a 1:1 Langmuir 
binding model using the BIAcore X100 Evaluation Software (Version 2.0.1). 
 
HLA subtype construction, purification, and analysis 
HLA-A*02:01, 02:02, 02:03, 02:05, 02:06, 02:07, 02:11 sequences were 
obtained from The HLA Factsbook(139). HLA subtype MHC complexes were 
generated using a modified protocol(140). In brief, each HLA-A*02 subunit as 
well as the 2-microglubulin (B2M) subunit were overexpressed in E. coli in 
inclusion bodies and then solubilized in 8M urea. The RMF peptide, HLA-A*02 
solution, and B2M urea solutions were mixed together in the refolding buffer at 
4 degree for 2 days. The refolding solution was further concentrated and buffer 
exchanged into PBS. The desired MHC complex was purified by size 
exclusion chromatography (SEC) using an AKTA FPLC system.  
 
Crystallization 
ESK1 Fab fragments were produced from intact IgG ESK1 and purified with 
the Pierce Fab Purification kit. Fab fragments were concentrated to 100 uM, 
mixed with equimolar HLA-A*0201 receptor/-microglobulin/RMF complex, 
and equilibrated on ice for one hour. The sample was concentrated to 12.5 
mg/ml using a 10 kDa cutoff Amicon concentrator and exchanged into 50mM 
Tris (hydroxymethyl) aminomethane, 25 mM NaCl, pH 7.5, and 0.5 mg/ml 
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RMF peptide. Crystals grew within 1 – 3 weeks when the protein solution was 
mixed 3:1 with Microlytic MCSG-1 H9 solution (0.1 M Bis-Tris HCl pH 5.5, 25% 
(w/v) PEG 3350) at 18° C in sitting drops. Crystals were whisked through 
Paratone-N for 10-20 seconds and cryocooled in liquid nitrogen prior to data 
collection. 
 
 
Data collection and refinement 
Diffraction data to 3.05 Å were collected remotely at Beamline 12-2 at the 
Stanford Synchrotron Radiation Laboratory (141) under a nitrogen cryostream 
on a Pilatus detector. Data were processed with HKL3000 (142) and XDS 
(143). The structure was solved by molecular replacement using the structures 
of HLA-A2 (PDB 3HPJ) and the Fab fragment from antibody HC84-1 (PDB 
4JZN) using MOLREP (144) and Phaser (145). The structure was refined with 
REFMAC (146) with manual rebuilding with Coot (147). Processing and 
refinement statistics are provided in Table S1. The crystal structure 
coordinates and diffraction reflections are deposited in the PDB (4WUU). 
 
 
Structure analysis and modeling 
Modeling was performed with PyMol and Coot. Interaction surface properties 
were calculated with Pisa (148).  
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RESULTS 
 
OverallStructure 
 
The ESK1 Fab fragment binds primarily the first five residues, RMFPN of the 
peptide-MHC (pMHC). The ESK1 Fab variable domain contacts 160 Å2 (Figure 
3.1A). RMF peptide interacts with 873 Å2 of the HLA receptor with a similar 
structure to the HLA-A02 without peptide (149). ESK1 antibody-HLA contacts 
890 Å2  and the total ESK1-pMHC surface is 1050 Å2 (Figure 3.1BC). The 
variable domains of ESK1 bind to both the peptide RMF and HLA-A02 
molecule (Figure 3.1D). The binding region of the ESK1 Fab is predominantly 
contacting the first five amino acid residues of RMF with the interactions of the 
CDR loop with the pMHC. Four tyrosines on the heavy CDRs stabilize the 
interface.  (Figure 3.1E).  
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Figure 3.1 Overall structure of ESK1 Fab. A.The cartoon backbone rendering 
of the ESK1/pMHC complex is shown. HLA-A*02:01and β2-microglobulin are 
colored blue and magenta respectively. HLA helices α1 and α2 in the RMF 
binding site are red. The light and heavy antibody Fab fragments are cyan and 
orange respectively and are labeled by their variable (VL, VH,) or constant (CL, 
CH) domains. B. The surface of the variable domains of the antibody is shown 
where the heavy chain contact surface is colored olive and the light chain 
contact surface is lime. C. The top down view of the HLA surface is shown 
with the HLA contact surface colored yellow and the RMF contact surface 
colored pink. D.The variable loop regions of the light and heavy chains are 
shown at the antigen binding site. VL loops L1, L2, and L3 are colored blue, 
purple, and magenta, respectively. VH loops H1, H2, and H3 are colored 
yellow, red, and green respectively. E. The top-down view shows the RMF 
binding site with the variable loops circled. (Conducted by N. Ataie). 
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Comparison to other TCRS and TCR-like antibodies 
 
We compared the structure of ESK1 + HLA-A*02 to HLA-A*02 with twenty 
other TCRs and TCR mimic antibodies (134, 150–156) to determine the 
mechanism for the 1000-fold higher affinity for ESK1 compared to these other 
ligands (Figure 3.2). The four TCR mimic antibodies compared differ widely in 
binding orientations. None of the other three antibodies binds to the same 
arginine cluster as ESK1. ESK1 CDR loops reach HLA-A*02 regions 
untouched by TCRs that interact with the HLA arginine cluster. Compared to 
the sub-nanomolar affinity of ESK1, TCRs typically bind with a maximum of 1 
μM binding affinity (157). While ESK does not have the largest contact surface 
compared to the other pMHCs, it has the highest affinity (Table 3.1)(158, 159). 
73 
 
Figure 3.2. Structural comparison between ESK1 and other TCRs and TCR-
like antibodies. A. Structural alignment between ESK1 and 20 TCR/HLA-
A*02:01/peptide structures shows that ESK1 CDR loops reach regions of HLA 
α2 that TCR loops do not. This includes the circled arginine-rich region: 
Arg108, Arg169, and Arg170. The blue ESK1/pHLA structure has VH domains 
H1, H2, and H3, colored yellow, red, and green, respectively. B. Structural 
alignment of TCRm antibody/HLA-A*02 structures shows that antibodies are 
more diverse in binding position and angle than TCRs, though none binds to 
HLA via the arginine-rich ESK1 binding site. C-F. The footprints of three TCRs 
and ESK1 show that TCRs bind to the mid-helical region, in contact with the 
peptide, whereas ESK1 reaches beyond the canonical TCR binding site. 
(Conducted by N. Ataie). 
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Table 3.1. A comparison of interface interactions between ESK1/pHLA-
A*02:01 and three TCR/HLA-A*02:01 structures showing the contact surface 
area and binding free energy calculated from experimental dissociation 
constants. ESK1 has the strongest binding free energy despite having a total 
contact surface area comparable to TCRs. Surface areas were calculated with 
PISA (Conducted by J. Xiang). 
 
 
 
 
Peptide Binding Specificity 
 
ESK1 binds the HLA receptor where RMF Arg1 is buried (Figure3.3A). ESK1 
primarily interacts with RMF Arg1 and Pro4. RMF Met2, Phe3, Ala6, Phe7, 
and Leu9 side chains contact the bottom of the HLA peptide binding region 
(Figure3.3B). Asn5 and Tyr8 face the solvent and do not contact ESK1.  
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Figure 3.3. Peptide interactions. A. RMF binds HLA with Met2, Phe3, Pro7, 
and Leu9 facing the HLA receptor and Arg1, Pro4, Asn5, and Tyr8 facing 
solvent and/or antibody. The heavy and light chains are in orange and cyan. 
Arg1, Pro4, and Asn5 are within van der Waals distance to ESK1. B. RMF 
Arg1 is located near hydrogen bond distance of Ser102. Arg1 also forms 
potential hydrogen bonds to HLA Thr163 and Trp167 and is within van der 
Waals distance to ESK1 Tyr104. Also shown is the proximity of RMF Pro4 to 
ESK1 light chain Asp94 (Conducted by N. Ataie) 
 
 
In order to probe the structural requirements of the ESK1 antibody to 
the HLA-A02/RMF complex, we made substitutions along the length of the 
RMF peptide. Substitutions were made throughout RMF and ESK1 binding to 
the peptide/MHC complex was measured in the TAP1/2 deficient T2 
lymphoblastoid cell line by pulsing various peptides onto HLA-A02. 
 Substitution at position 1with citrulline, sterically similar to arginine, but 
uncharged, eliminated binding. Lysine substitution at position 1 decreased 
binding 40-fold. Substitution at position 1 with ornithine, similar to lysine, but 
shorter by a carbon atom, or with histidine, eliminated ESK1 binding (Figure 
3.4). Overall, the binding data support a highly specific fit of the ESK1 
electrostatic lock for arginine. Arg1 is near several charged residues in a 
A B
C
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buried hydrophobic pocket capped by a highly negatively charged loop from 
the ESK1 heavy chain.  
 
Figure 3.4. Binding results of amino acid substitutions at position 1 of RMF. 
Flow cytometry binding results of a series of substitutions at position 1 of the 
RMF peptide are shown with a chemical depiction of the substitution. Regions 
harboring positive charge are colored blue and those with negative charge, 
red. Compared to arginine (A), citrulline (B) has similar van der Waals packing 
and hydrogen bonding but the lack of charge drastically reduces binding. (C) 
Substitution of lysine, which retains the positive charge of arginine, has forty-
fold lower affinity than arginine, but much greater affinity than citrulline. (D) 
Substitution with histidine, with no similarity to arginine, exhibits no binding. (E) 
Binding pocket of RMF Arg1. 
 
This pocket acts as an electrostatic lock in which the negatively 
charged dipoles of the backbone carbonyl oxygens of Ser102, Gly103, and the 
sidechain of Asp106 converge without countercharge, creating a buried space 
of focused negative charge. Tyrosine at position 1 does not provide the 
countercharge needed to fit the electrostatic lock. The crystal structure can 
help reveal the factors driving specificity and cross reactivity of ESK1 toward 
other peptide/MHC epitopes. Substitutions along different positions in the 
peptide demonstrate the sensitivity of various residues.  
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A loop from the light chain partially shields RMF Pro4 from solvent. 
Asp94 of the light chain is positioned 3.4 Å away from Pro4. Substitution to 
glycine, alanine, or serine at RMF position 4 does not significantly affect 
binding, but substitution to cysteine decreases binding ten-fold (Figure3.5). 
Cysteine modeled into position 4 of RMF sterically clashed with Asp94. 
Surprisingly, the substitution of tryptophan at position 4 showed no loss in 
binding affinity. Tryptophan modeled into that position forms potentially 
favorable cation-π interactions with HLA Lys66. Large residues modeled into 
the fifth position clash with nearby residues. Other large bulky residues at 
position five decrease binding over ten-fold (Figure3.5). 
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Figure 3.5.Binding avidity of WT1 substituted peptides relative to RMF, as 
determined by flow cytometry. EW is a peptide (QLQNPSYDK) unrelated to 
RMF, isolated from Ewing sarcoma, used here as a negative control. Results 
were normalized to RMF binding. O corresponds to ornithine and Ct 
corresponds to citrulline; all other amino acid abbreviations are standard. 
 
HLA-A*02 subtype specificity 
 
HLA-A*02 alleles vary widely across different ethnic populations. HLA-A*02:01 
is the most commonly found variant, especially in Caucasians in the United 
States, but other subtypes are more common in other ethnic groups. Six 
subtypes are found in hundreds of millions of people worldwide that differ from 
HLA-A*02:01 through 1 to 4 amino acid changes in the side walls of the 
peptide binding pocket. Models were built of several common HLA-A*02 
subtypes, using crystal structure coordinates of the subtype if available 
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(A*02:03, A*02:06, A*02:07), to predict the effect of binding to RMF and ESK1. 
All residues that differ between A*02:01 and the other six subtypes do not 
contact ESK1 (Figure 3.6). Modeling also predicts that RMF binding would be 
retained across these A*02 subtypes. We predicted and experimentally 
confirmed that these six subtypes bind RMF and ESK1 (Table 3.2) by surface 
plasmon resonance using immobilized, biotinylated HLA+RMF. The measured 
affinity of ESK1 to RMF + A*02:01 is 13.2 nM, lower than measured by the 
whole cell method. All six HLA variants bind to ESK1 with similar or higher 
affinity (1.1 nM for A*02:11 to 23.6 nM for A*02:02), supporting patient 
compatibility.  
 
Figure 3.6.Mapped HLA-A*02-subtype differences. Mapped positional 
differences between the subtypes are colored red: A*02:02, orange: A*02:03, 
green: A*02:05, blue: A*02:06, magenta: A*02:07, and yellow: A*02:11. The 
ESK1 footprint is shown in light blue. None of the residues that vary between 
A*02 subtypes contacts ESK1 (Conducted by N. Ataie).  
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Table 3.2. Characterization of ESK1 binding to HLA-A*02 variants with RMF. 
Binding parameters were measured by surface plasmon resonance on a 
Biacore X100 (Conducted by J. Xiang). 
 
Subtype kd 
[1/s] 
Error in kd 
[1/s] 
ka 
[1/Ms] 
Error in ka 
[1/Ms] 
KD 
[nM] 
Error in KD 
[nM] 
A0201 1.35E-02 6.70E-04 1.02E+06 4.80E+04 13.2 0.90 
A0202 1.40E-02 4.10E-04 5.91E+05 4.30E+04 23.6 1.9 
A0203 1.06E-02 2.70E-04 5.24E+05 3.10E+04 20.3 1.3 
A0205 5.79E-03 1.10E-04 1.03E+06 1.90E+04 5.6 0.2 
A0206 1.91E-03 2.30E-05 9.32E+05 7.50E+03 2.1 0.03 
A0207 1.50E-03 3.00E-05 9.53E+05 1.00E+04 1.6 0.04 
A0211 9.30E-04 1.80E-05 8.40E+05 5.50E+03 1.1 0.02 
 
Structure-based prediction of potential ESK1 off-target toxicity 
 
A major advantage of antibody over small-molecule therapeutics is that toxicity 
tends to be more predictable and related to mechanism of action due to their 
higher specificity (160). Nevertheless, off-target binding is still a serious 
concern for immunotherapy. Currently, specificity is enforced by 
counterscreening antibody candidates against nonspecific targets such as cell 
lysate or MHC receptors bearing untargeted antigen peptides. We 
demonstrate for the first time that structural knowledge and simple 
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computational analysis can be used to predict off-targets and further engineer 
TCRm specificity. 
Given the structural and biochemical data supporting the key binding 
interactions of the ESK1 antibody to RMF positions Arg1, Phe3, and Pro4, we 
performed a BLAST search for similar expressed human peptide sequences. 
The peptides were then subjected to binding affinity analysis using 
NetMHC(138) to predict peptides with a Kd to HLA-A*02:01 < 500 nM. Using 
artificial neural networks, NetMHC predicts MHC peptide binding with 78% 
accuracy. The two highest-ranking peptides were identified to be from 
MED13L (mediator complex subunit 13-like), RMFPTPPSL, and PIGQ 
(phosphatidylinositol glycan anchor biosynthesis, class Q), RMFPGEVAL, and 
were tested as potential off-targets to validate our hypothesis. ESK1 bound 
cell surface MHC with either peptide (Figure 3.7). Structural modeling supports 
compatibility of these two peptides with HLA-A*02:01 and ESK1 binding. In 
silico mutagenesis of the RMF peptide in the ESK1/HLA/RMF crystal structure 
showed that the sequences in the MED13L and PIGQ peptides could be 
accommodated with little change to HLA and ESK1 binding surfaces.  
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Figure 3.7.Validation of predictions of potential ESK1 off-target epitopes. 
ESK1 binding was measured by flow cytometry. Relative binding was 
normalized to 25 μg/mL RMF. Relative binding of a scrambled control peptide 
or two identified peptides derived from MED13L and PIGQ is shown. 
 
Studies on normal donor peripheral blood monocyte cells showed potential off-
target binding of ESK1 to a small subset of healthy donor CD19 + B-cells, 
which were WT1 negative. In this way, it is possible that ESK1 binding to this 
subset of cells may be attributable to non-WT1-derived epitopes, which data 
suggests could be from two or more of the identified off target epitopes 
MED13L or PIGQ. We observed higher expression of off-target genes 
MED13L and PIGQ in ESK+ CD19+ cells, when compared wo ESK-/CD19+ 
cells (Figure 3.8).  
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Figure 3.8. Gene expression of MED13L, PIGQ, and WT1 in PBMC with low 
and high binding of ESK1. PBMC from a normal healthy donor were taken and 
sorted for CD19+ ESK- and ESK+ populations by FACS. RNA was extracted 
and qPCR for MED13L, PIGQ, and WT1 genes was performed and 
normalized to TBP.  
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DISCUSSION 
 
TCRs with moderate affinity (Kd = 1–100 μM) to antigens are produced 
in the body and provide the basis for a number of therapeutic agents, including 
soluble TCR-based constructs, TCR engineered cells, and peptide vaccines. 
TCR-based drugs have several potentially serious limitations. One is their 
restriction to a specific HLA subtype, reducing the potential patient population 
that may benefit from the therapeutic approach to a small fraction of afflicted 
patients. An additional limitation is cross-reactivity of typically low affinity TCRs 
to other peptide epitopes presented by MHC molecules that has resulted in 
severe toxicity in human trials(135). The current state of the art of antibody 
engineering is more advanced than with TCRs, allowing for greater structural 
and binding diversity. Here we present the first use of structural and 
biochemical characterization of the interaction of a TCRm antibody to its 
cognate pMHC epitope in an effort to investigate and overcome both these 
limitations. 
An essential feature in the development of a TCRm is high specificity to 
the molecular complex of both the MHC molecule and presented peptide 
simultaneously, as mAb reactivity with the MHC alone would confer reactivity 
with every nucleated cell. Phage display can produce much higher-affinity 
TCRm antibodies such as ESK1 than occurs in vivo with TCRs, while 
simultaneously selecting against antibodies that may cross-react with the MHC 
complex alone. Second, the high affinity of TCRm antibodies allows 
pharmacologic dosing and retention of the drug at the cancer cell site in vivo. 
85 
The TCRm, ESK1, binds with subnanomolar affinity, over 1000-fold more 
tightly than natural TCRs. Our data demonstrate the molecular basis for both 
the specificity and the affinity of ESK1. 
Surprisingly, the high-affinity binding was mainly driven by interactions 
between the antibody and HLA receptor that are restricted to regions identical 
with or similar between at least six common HLA-A*02 subtypes that vary in 
different ethnic groups worldwide. This result led us to hypothesize that ESK1 
could bind to the same WT1 peptide epitope when presented by various other 
HLA-A*02 subtypes in addition to HLA-A*02:01. Experimental confirmation of 
ESK1 binding to these HLA-A*02 variants extends the potential scope of ESK1 
therapy to millions of additional patients. In addition to its pharmacologic 
advantages, this unexpected finding shows that the use of a TCRm therapy 
may be a novel strategy to overcome the limits of HLA-subtype restriction of 
typical TCR-based therapy and therefore have broader therapeutic 
applications. 
Naturally occurring TCR can bind off-target peptides(161, 162). We 
were able to use the structural information to predict potential cross-reactive 
peptides of ESK1 in humans. When bound to the HLA receptor, ESK1 
primarily interacts with the N-terminus of RMF. As a consequence, other 
peptides expressed in humans that are homologous to the N terminus of RMF 
and that bind to HLA-A*02 with the anchor residue at position 9 but that differ 
at positions 5–8 in the C terminus might be ESK1 off-targets. We confirmed 
that such peptides in complex with HLA-A*02:01 can bind to ESK1 on peptide-
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pulsed T2 cellsin vitro. Thus, it may be possible to account for both structure 
and potential off-targets using a bioinformatics approach as we have shown 
with ESK1 mAb with WT1/HLA-A*02:01. The determination of whether these 
alternate targets are processed and expressed on the surface in normal 
tissues would be challenging, but identification of these targets in advance of 
clinical trials may allow for appropriate prospective clinical observation. In 
conclusion, we demonstrate for the first time that detailed, integrated 
structural, genetic, and biochemical analysis can provide a platform for 
appropriate selection and stratification of patient in efforts to maximize 
treatment efficacy and minimize toxicity. As such, this structure-based 
approach may serve as a key step toward personalized and precision 
medicine. 
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CHAPTER 4: IDENTIFYING AND BYPASSING MECHANISMS OF 
RESISTANCE TO ESKM IN ACUTE LEUKEMIA3,4 
 
 
INTRODUCTION 
 
Previous work has demonstrated that ESKM is an effective mAb for the 
treatment of acute leukemias, including both ALL and AML. Widespread 
expression of WT1 is seen in multiple cancers, including both ALL and AML. 
Limited expression in normal tissues has also been observed, making WT1 an 
attractive target. Much work has been dedicated toward targeting WT1, either 
through vaccination with peptides derived from WT1, or adoptive T-cell 
therapy with TCR directed toward WT1+ tumors presenting peptides on MHC-
I.  
Work in our group has shown that a TCRm mAb directed toward WT1 is 
an effective therapeutic strategy to treat acute leukemias. ESKM is a TCRm 
that targets a specific 9 amino acid epitope, RMFPNAPYL, derived from the 
oncoprotein WT1 that is presented on HLA-A02+ tumors. This has shown to 
be effective in treatment both in vitro and in vivo against human acute 
leukemias. While initial response is seen to ESKM, it is not curative even 
under continuous therapy. Thus, further investigation into strategies that may 
                                                 
3 Modified from Dubrovsky LD, Pankov D, Brea EJet al.  Blood. 2014 and 
Dubrovsky LD, Brea EJ, et al. Submitted 2016 
4 Some experiments were designed and conducted by or in collaboration with 
Leonid Dubrovksy and Dmitry Pankov as noted in the text. 
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lead to synergy between ESKM and targeted therapy or immunotherapy is 
warranted. 
Acute lymphoblastic leukemia contain a fusion BCR-Abl protein, from 
the t(9:22) translocation, also referred to as the Philadelphia translocation 
(Ph+) in up to 20% of cases in adults, and 5% in children(83). The BCR-Abl 
fusion protein is necessary for oncogenic transformation and hyperproliferative 
phenotype of leukemia cells containing this translocation, making it an 
attractive theapetuic target. Imatinib was approved by the FDA for treatment of 
Ph+ chronic myelogenous leukemia, but this treatment was also tested in Ph+ 
ALL as well. Responses were not as drastic or durable in ALL as CML with 
Ph+ translocation, but more potent BCR-Abl inhibitors such as dasatanib are 
currently approved as part of therapy in Ph+ ALL(163).  
We predicted that use of BCR-Abl inhibitors such as dasatanib, which 
demonstrated activity in ALL could be useful as a combination therapy with 
ESKM in BCR-Abl+ WT1+ leukemias. ESKM has shown to be effective in 
treatment of th BCR-Abl translocated, WT1+ cell line BV173 (50).  
Mechanisms of resistance to ESKM  
While use of kinase inhibitors in combination with ESKM has shown potential 
for cure of disseminated leukemia in murine xenograft models of human ALL, 
no specific FDA approved kinase inhibitors are available for AML. We showed 
activity of ESKM in vitro and in vivo against human AML cell lines and patient 
derived xenografts (50, 130). While response to ESKM was seen against the 
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AML cell lines in vivo, responses were not durable and the leukemia quickly 
escaped ESKM therapy.  
 We evaluated mechanisms of ESKM resistant to leukemias by 
examining whether the leukemia cells downregulated target, alteration of 
sensitivity to ESKM mediated killing in vitro, and paucity of effector cells 
available for ADCC mediating killing. Downregulation of target has been seen 
previously in resistance to antibody therapy in the case of rituximab for non-
Hodgkins lymphoma (164). Resistance due to downstream mutations of a 
receptor have been seen with antibodies such as cetuximab in colorectal 
cancer(165). Polymorphisms in Fc receptor encoding gene FcRIIIahas also 
been linked to lack of efficacy of antibodies(166). Lack of effectors has also 
been seen as a mechanism of resistance or failure of antibody therapy. 
 ESKM has activity solely through antibody dependent cellular 
cytotoxicity, and lacks complement mediated cytotoxicity or direct killing ability 
in the absent of human effector cells such as neutrophils, macrophages, and 
NK cells(50). Activity of ESKM can be increased by a defucosylated Fc 
enhanced variant in comparison to the ESK-1 with normal fucosylation (130).  
 We therefore proposed looking at mechanisms of resistance to ESKM. 
We utilized an immunodeficient mouse strain lacking B cells, T cells, and NK 
cells, with macrophages and neutrophils as the main effector cells. This 
allowed us to study resistance to ESKM and discover approaches to enhance 
sensitivity as combination therapy.  
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MATERIALS AND METHODS 
 
ADCC 
ADCC was evaluated by chromium release assay, incubating target cells in 50 
µCi Cr51 for 1 hour before 3 washes, with the determined optimal ADCC time 
of 6 hours. Three effector to target (E:T) ratios were used (either 10:1, 30:1, 
and 100:1 or 25:1, 50:1, and 100:1). Effector peripheral blood mononuclear 
cells (PBMCs) were derived from healthy donors by Ficoll density 
centrifugation, after obtaining informed consent on a Memorial Sloan-Kettering 
institutional review board–approved protocol. This study was conducted in 
accordance with the Declaration of Helsinki. 
 
One to three day ADCC assay was performed by incubating healthy donor 
PBMCs isolated by Ficoll with target leukemia cells at E:T 50:1 and 25:1 in 
triplicate. Treatment groups had ESKM added to media at 3 µg/ml, while 
control groups had no antibody added. The SET2 cells used in these assays 
were GFP tagged, and flow cytometry was utilized to measure the 
concentration of live (DAPI negative) GFP positive cells in solution compared 
to total number of cells. Constitutively on GFP was transduced with a lentiviral 
GFP vector specifically for the purpose of easily identifying these cells in the in 
vitro ADCC assays. 
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BV173R Synthesis 
The BV173R cell line was engineered to harbor the T315I BCR-ABL using a 
Clonetech pMSCV Puro vector with the T315I BCR-ABL gene, a kind gift from 
Charles Sawyers (167). BV173-luc-gfp cells were transduced with the 
retroviral vector, selected, and expanded in media with puromycin. The 
presence of the resistant T315I mutation was confirmed by polymerase chain 
reaction (PCR) for the plasmid, as well as ABL sequencing of cDNA and 
genomic DNA in the resultant BV173R cell line. 
 
Flow cytometry  
Fortessa flow cytometer (BD Biosciences) was utilized for all flow cytometry 
measurements. Evaluation of ESKM binding to target cells and cell surface 
HLA-A*02:01 expression was done by direct flow cytometry. ESK was labeled 
with APC using the Innova Biosciences Lightning-Link Allophycocyanin (APC) 
kit.  
For both in vitro and in vivo studies, APC or PE tagged BB7 antibody 
(BioLegend) was utilized to measure HLA-A02 expression on cell surface. 
After mouse BM resection in xenograft models, APC-tagged ESK1 antibody 
(Innova Biosciences - Lightning-Link® Allophycocyanin), was used to measure 
RMF expression on cell surface. Xenografted SET2 cells were identified by 
CD33-BV711, and BV173 by CD19-PE (BioLegend). While the Xenografted 
SET2 and BV173 leukemia cells were both GFP positive, it was very dim in 
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the cell lines used for in vivo studies, and was therefore not used for flow 
cytometry. 
PCR analysis 
Minimal residual disease of cell lines in mouse bone marrow (BM) was 
evaluated using custom-made primers to the Firefly Luciferase gene with 
SYBR Green using GAPDH as a control. 
 
 
Trials of ESKM with TKIs in vivo in mice 
Trials of ESKM were done using xenograft models, in nonobese 
diabetic/severe combined immunodeficient (NOD/SCID) mice with IL2 γ 
receptor knockout (NSG) mice engrafted with BV173 Ph+ leukemias. The 
BV173 and BV173R cell lines used for all in vivo studies stably expressed the 
firefly luciferase gene, and disseminated engraftment of leukemia was 
confirmed 6 days after tail vein injection by bioluminescent imaging (BLI) 
before treatments. Mouse research was approved by the MSKCC institutional 
review board under protocol 96-11-044. 
Preliminary drug dosing studies in NSG mice demonstrated the maximum 
tolerated dose (MTD) of imatinib to be 50 mg/kg intraperitoneally (IP) daily, 
with higher dosing resulting in diarrhea and severe toxicity. Dasatinib was also 
initially tested, with the MTD of 40 mg/kg (0.8 mg/mouse) resulting in no 
appreciable short-term toxicity. However, longer-term trials of dasatinib 
resulted in mouse sudden deaths, and the dose was therefore lowered for 
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subsequent experiments to 20 mg/kg and then to 10 mg/kg to eliminate drug-
related mortality. For mice receiving ponatinib, the initial published dose of 5 
mg/kg showed inadequate leukemic affect without any evident health side 
effects, and therefore ponatinib doses were increased to 10 mg/kg. At this 
dose, toxicity was comparable with 50 mg/kg of imatinib, with intermittent 
diarrhea and poor growth. 
All TKIs, including imatinib, dasatinib, and ponatinib, as well as plerixafor, 
were purchased from Selleckchem or Fisher Scientific. The plerixafor stock 
solution was made in phosphate-buffered saline at 200 µg/mL and stored at 
room temperature. Mice received 1 mg/kg (20 µg/mouse) daily by IP injection, 
as was used in previous studies(168). No toxicity was noted during therapy. 
Before its use in vivo, stock solutions of TKIs were prepared in dimethyl 
sulfoxide (DMSO), with the scheduled dose of TKI in 50 µL DMSO per mouse. 
All TKIs and ESKM treatments were administered IP at these schedules: 
ESKM 100 µg twice weekly and TKIs daily. Male NSG mice, aged 6 to 8 
weeks, were purchased from Jackson Labs(169). Three million leukemic cells 
(BV173 or BV173R) were injected per mouse by tail vein on day 0. 
Luciferin/luciferase BLI was then performed on day 6, with therapy 
commencing immediately after confirmation of equivalent levels of 
disseminated leukemia by imaging. IVIS 200 and IVIS Spectrum machines 
were used for BLI. 
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ESKM therapy in vivo  
Luciferase tagged SET2, BV173, and SET2-S cell lines were used in all 
xenograft models, and leukemia growth was measured by bioluminescent 
imaging (BLI) using the IVIS Spectrum, with intraperitoneal luciferin injections 
5 minutes prior to imaging. Day 0 of studies were defined as day of leukemia 
injection by tail vein. Because no differences were noted in therapeutic effect 
between biweekly ESKM dosing of 100 µg and 50 µg per dose, 50 µg ESKM 
biweekly IP were used in these studies. GM-CSF was dosed at 1 µg, 
administered daily IP. For SET2-S cell line experiments, the two experimental 
groups of five mice each were administered doxycycline via food pellets (625 
mg/kg) (Harlan-Teklad) starting on day 6 and continued until the end of the 
experiment. 
 
Cloning, vector construction, and purification of SET2-S 
The 3rd generation lentiviral vector pLV was obtained from VectorBuilder 
(Santa Clara, CA, USA) and the human CDKN1B (p27kip) cDNA was cloned 
was under the TRE3G inducible promoter with a C-terminal FLAG tag and 
IRES for expression of tdTomato. The pLV vector also had constitutive 
expression of rtTA3 under the CMV promoter. HEK293T cells were used to 
produce lentiviral particles using the pRSV (Addgene #12253), pMDL 
(Addgene #12251), and pMD2.G (Addgene #12259) vectors along with the 
CDKN1B gene (coding for p27Kip1 protein). Viral supernatant was harvested 
from HEK293T cells and used to transduce SET2 GFP-Luciferase expressing 
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cells using spinfection at 1x106 cells in 8 µg/ml polybrene with viral 
supernatant at 2000x g, 2 hours, for two rounds on transduction. A clonogenic 
assay was set up to insure 100% purity of transduced SET2-S cells. Colonies 
positive for tdTomato after 2 µg/ml doxycycline induction were pooled and 
expanded for downstream use.  
Flag-tag specific antibody used in Western blot assay were purchased from 
Cell Signaling Technologies (#14793). Doxycycline was obtained from Sigma. 
SET2 stably transduced with CDKN1B were exposed to increasing doses of 
doxycycline for 48 hours and 96 hours. Cell-Titer Glo (Promega) was 
performed at indicated time points to assess viability. Flow cytometry studies 
for tdTomato expression was performed on the Accuri C6 flow cytometer (BD 
Biosciences). Flow cytometry for ESKM binding was performed using ESK 
conjugated with APC fluorophore. Cells were stained with 3 µg/ml ESK-APC 
for 45 m on ice. DAPI was used for viability assessment. Cells were analyzed 
using the Fortessa flow cytometer (BD Biosciences) 
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RESULTS 
 
ESKMtherapyofPh+ ALLinNSGmice 
 
Imatinib is a tyrosine kinase inhibitor that targets Ph+ BCR-Abl. BV173 is a 
human ALL cell line confirmed to have Ph+ BCR-Abl translocation, and is also 
HLA-A*02:01+(170).BLI confirmed engraftment of luciferase-tagged BV173 
Ph+ ALL in NSG mice 6 days after tail vein injection. Mice were randomly 
assorted into 4 groups: no therapy, imatinib only, ESKM only, or a combination 
therapy. ESKM therapy was superior to imatinib therapy after 5 weeks of 
therapy (78% vs 52% tumor growth reduction, p< .01) (Figure 4.1A).The 
combination of ESKM and imatinib was superior tosingle agent therapy (P < 
.001), decreasing tumor growth by 94% (Figure 4.1B) BV173 cells were 
isolated from bone marrow and analyzed by flow cytometry for HLA-A 
expression and ESKM binding immediately after completion of therapy (Figure 
4.1C), with detectable BV173 cells in all groups.  
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Figure 4.1. BV173 human ALL xenograft NSG mouse model with combination 
imatinib and ESKM at optimal efficacious doses. Mice received 5 weeks of 100 
ug ESKM bw, 50 mg/kg imatinib qd, combination therapy, or no therapy 
(control). Error bars show 5th and 95th percentiles. A. Leukemic growth as 
measured by bioluminescent imaging for each of the four groups of mice. B. 
BLI at end of therapy (5 weeks of therapy) for each of the four groups of mice. 
C. Flow cytometry for HLA-A02 and ESK binding. Three out of five mice where 
randomly chosen from each of the four groups. BM was harvested and cells 
were evaluated by flow cytometry. Cells were gated on human CD19+ 
population and evaluated for BB7.2 (HLA-A*02:01) and ESK binding 
(Conducted by L. Dubrovsky). 
ESKM therapy in combination with dasatanib 
 
Dasatinib is a more potent FDA approved second-generation TKI of Abl than 
imatinib with activity (171).Similar to as was evaluated for imatinib, dasatinib 
was administered at 40 mg/kg qd IP in combination with ESKM. The 
combination therapy lead to durable response and molecular remission in 75% 
of mice (Figure 4.2), which was confirmed by quantitative PCR of bone 
marrow 3 weeks after the end of therapy (Table 4.1 MRD < 0.001%). No 
remissions were seen in mice treated with single agent therapy. The single 
mouse treated with combination ESKM and dasatanib that relapsed had CNS 
tumor burden. This is notable because antibodies do not readily enter the CNS 
(172). At this dasatinib dose, all mice receiving the TKI became ill about 1 
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week into therapy, with 1 mouse fatality on day 8 of treatment. All dasatinib-
treated mice sustained temporary BLI remissions, but those not treated with 
ESKM relapsed 2 to 3 weeks after cessation of therapy. 
 
Table 4.1. MRD from NSG mouse bone marrow. Quantitative PCR for the 
luciferase gene from mouse bone marrows of three mice treated with 
combination therapy ESKM and dasatanib whose images were negative on 
BLI 3 weeks after end of therapy with high dose dasatinib for 11 days and 
concurrent ESKM for 4 weeks. The positive control mouse was treated with 
dasatinib only and had positive BLI signal (relapsed). BV173 cells mixed with 
healthy donor cells (negative for luciferase gene) at known ratios and qPCR 
done on mixture as control. 
 
Sample Calculated Gene Expression 
BV173 cells 100% positive Control 100.00% 
BV173 1% cells positiveControl 0.37% 
BV173 0.01% cells positiveControl 0.02% 
Cell Line Negative Control <0.001% 
ESKM + Dasatinib treated Mouse #2 <0.001% 
ESKM + Dasatinib treated Mouse #3 <0.001% 
ESKM + Dasatinib treated Mouse #5 <0.001% 
Dasatinib alone treated mouse positive Control 2.22% 
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Figure 
4.2CombinationtherapywithESKManddasatanibshowssuperioritytoimatinibintre
atmentofxenograftmodelofALL. Errorbarsshow 5thand 95thpercentiles. (A) 
BV173 growthmeasuredbyBLIinmicetreatedwithhighdosedasatinibtherapy (40 
mg/kgqdfor 8 daysthenreducedto 20 mg/kgx3 daysforatotal 11 
daysoftreatmentandthendiscontinuedsecondarytohightoxicity), ESKMonlyfor 4 
weeks, combinationtherapyandcontrol (notherapy). (B) BLIonDay 55, 3 
weeksafterendoftherapy. Mouse #1 
incombinationdasatinibwithESKMdiedsecondarytodasatinibtoxicityonDay 13, 
andmouse #4 appearstohaverelapsedinCNS. (C) 
HighdosedasatinibplusESKMgroupBLIimages, 
showingprogressionofrelapseinmouse #4. (D) 
LeukemicgrowthmeasuredbyBLIinmicetreatedwithdasatinibtherapyat 20 
mg/kgqdfor 18 days, thendiscontinuedduetohightoxicity. 
ESKMwasgiventosixmice (day 18 today 42). Allmicerelapsed, 
thoughESKMmicerelapsedwasdelaryedsignificantlyandprolongedlifespanby 1 
week. Lastdatapointpertainstowhenmiceweresacrificedduetoillness. (E) 
BLIattheendofESKMtherapy (day 42). 
MicereceivedESKMfollowingdiscontinuationofdasatinib (Dasatinib→ESKM 1 
and 2) andcomparedtoonecage (5 mice) thatreceivednoadditionaltherapy. 
ESKMsalvagedmicehavesubstantiallylesstumorburdenthendasatinibonlymice. 
Allmicerelapsed (Conducted by L. Dubrovsky). 
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Therapy of T315I Resistant Ph+ Leukemia Therapy 
 
BV173R (TKI resistant T315I mutant) leukemia xenografted NSG mice 
were initially treated with ESKM, imatinib, dasatinib and concurrent 
combinations of imatinib plus ESKM and dasatinib plus ESKM. Only 3 weeks 
of therapy were given, as the leukemia proved resistant to the first andsecond 
generation TKIs. In contrast, ESKM retained full and equivalent efficacy 
against the resistant BV173R leukemia compared to TKI sensitive leukemia 
BV173 (Figure 4.3A) as quantified by luciferase imaging during treatment. 
These findings are consistent with in vitro studies indicating that in ADCC 
assays, ESKM is as active against BV173R as it is against BV173 (Figure 
4.3B). Dasatinib provided only modest slowing of leukemic growth with 
leukemic burden rising five-fold over the same time period. The combination of 
ESKM and dasatinib showed substantial reduction in leukemia burden, though 
no mice were cured. As in the prior experiments with BV173 treated with the 
combination ESKM plus dasatinib, relapse was lymphoidtumors rather than 
diffuse leukemia (Figure 4.3C).  
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Figure 4.3.  BV173R (with T315I mutation) treated with dasatinib 10 mg/kg 
and imatinib 50 mg/kg qd IP for 21 days with and without biweekly ESKM 
therapy (6 doses of ESKM). Error bars show 5th and 95th percentiles. A. 
Exponential growth curves, from start of therapy (day 6). The blue bar shows 
duration of TKI therapy and the red lines are doses of ESKM. B. The 
susceptibility of cell line BV173, resistant cell line BV173R (with BCR-ABL 
T315I mutation) to ESKM directed ADCC with human PBMCs and different 
effector to target ratios.C. BLI imaging at the end of ESKM/TKI therapy (day 
27). ESKM is superior to imatinib and dasatinib for treatment of resistant Ph+ 
ALL (Conducted by L. Dubrovsky). 
NSG mice engrafted with this T315I Ph+ resistant leukemia were then 
treated with the third generation drug, ponatinib. Leukemic regression was 
seen in all ponatinib treated mice, with negative BLI showing no disease at the 
end of therapy on day 34 (Figure 4.4A). Mice treated with ponatinib 
monotherapy subsequently developed systemic leukemic relapse within two 
weeks after end of treatment, while those treated with the combination of 
ESKM and ponatinib developed either focal lymphoid relapse (3/5), or had no 
evidence of disease (2/5) 4 weeks after completion of therapy (Figure 4.4B).  
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Figure 4.4. BLI of NSG mice engrafted with resistant T315I cell line BV173R. 
Therapy with ponatinib and ESKM began on day 6 after injection, and 
ponatinib dose was escalated from 5 mg/kg to 10 mg/kg on day 13 secondary 
to initial lack of side effects. All treatments ended on day 34. A. Median BLI 
values for all four treatment groups, with error bars indicating 5 – 95% 
confidence intervals. B. BLI imaging for ponatinib and ponatinib + ESKM 
treated mice 3 and 4 weeks after conclusion of therapy. All ponatinib-alone 
mice have diffusely relapsed leukemia, while combination therapy mice have 
focal tumor relapse or no evidence of disease by BLI. Mouse #2 showed no 
signal on day 62, which was an error in injection of luciferin(Conducted by L. 
Dubrovsky). 
 
In Vivo Leukemia Growth Characterization and Resistance to ESKM 
 
While ESKM was notably efficacious in Ph+ ALL, which allows for 
combination with TKI such as imatanib and dasatanib which can lead to 
durable response in xenograft models, AML has proven more difficult to treat 
in xenograft mouse models with ESKM.  
The AML cell line SET2 grows as discrete tumor cells in the BM (Figure 
4.5AB). Initial treatments of SET2 with ESKM resulted in modest, short-lived 
therapeutic effects (Figure 4.5C). Increasing E:T ratio by decreasing the 
number of injected SET2 cells from 3 x 106 to 0.5 x 106 per mouse improved 
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initial cytotoxicity, but ultimately did not prevent rapid leukemic overgrowth. 
Increasing E:T further with GM-CSF did not increase ADCC/ADCP potency in 
this model (Figure 4.5D).  
Pre-treatment of mice with ESKM prior to injection of leukemia, which 
should provide a situation of maximum effector to target ratio, did not change 
outcome when compared to therapy on already engrafted SET2 cells in the 
mouse BM (Figure 4.5E). Furthermore, after the first week of ESKM therapy, 
additional mAb doses had minimal efficacy of slowing leukemic growth (Figure 
4.5F), implying the outgrowth of a resistant clone or the failure of therapy after 
leukemic overgrowth past a certain tumor burden. 
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Figure 4.5. SET2 cell line engrafted xenograft NSG mouse model growth 
patterns. Error bars: 5th to 95th percentile. All BLI imaging and growth curves 
use exponential scale. A. IHC for CD33, outlining discreet SET2 cells in 
mouse BM with no therapy, 3 weeks after injection. B. CD33 IHC of SET2 
cells in mouse BM 3 weeks after injection on 2 weeks of ESKM therapy 
(started on day 6). C. In vivo SET2 growth quantification by BLI over time, with 
3 x 106 cells injected on day 0, with and without ESKM therapy. D. In vivo 
SET2 growth quantification by BLI over time with and without ESKM therapy. 
Effector to target ratios are increased from (c) with only 5 x 105 cells injected 
on day 0 and the addition of GM-CSF. E. SET2 growth by BLI quantification, 
comparing starting ESKM after leukemic BM engraftment (on day 6) to 
leukemic growth in ESKM pre-treated mice (ESKM injected 2 hours prior to 
injection of SET2). F. SET2 growth by BLI quantification comparing 4 weeks of 
continuous (bi-weekly) ESKM therapy to only 1 week of treatment(Conducted 
by L. Dubrovsky). 
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Selection of germline or epigenetic durable resistance in vivo and in 
vitro 
 
SET2 cells harvested from mouse BM likewise did not down regulate 
the target antigen as measured by flow cytometry or HLA-A02 (Figure 4.6AB). 
However, these data do not rule out other forms of intrinsic resistance such as 
the outgrowth of an ADCC/ADCP resistant clone. Therefore, SET2 cells were 
extracted from the BM of ESKM treated and untreated mice, and then 
passaged in naive NSG mice. The resistant tumor cells extracted from the 
ESKM treated mice showed no durable resistance to renewed ESKM therapy 
compared to their untreated counterparts (Figure 4.6C). 
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Figure 4.6. SET2 cell evaluation status-post harvest from murine BM. A. Flow 
cytometry for surface HLA-A*02:01 expression, showing no difference 
between SET2 cells harvested from control mice and those treated with 
ESKM. B. Same cells as in (a), evaluating for ESKM binding, showing no 
difference between cells extracted from ESKM treated and untreated mice. C. 
SET2 cells from ESKM treated and untreated mice were harvested and 
passaged into a secondary group of mice. Ten initial mice (5 control, 5 treated) 
had BM harvested, and the SET2 cells extracted by Ficoll from each mouse 
were injected into two mice, (a control mouse and an ESKM pre-treated 
mouse). Error bars: 5th to 95th percentile. BLI growth curve utilizing exponential 
scale. 
 
We also explored whether resistance to ADCC could be selected for in 
vitro, using healthy volunteer PBMCs as effectors and SET2 target cells. A 
three day ADCC assay with E:T 25:1 was set up, with flow cytometry used to 
evaluate cytotoxicity and HLA expression. No plateau in killing of SET2 was 
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observed, and HLA-A*02 expression actually increased, likely due to cytokine 
release by the effector cells (Figure 4.7A-B).  
Increasing E:T to 50:1 greatly improved cytotoxicity overnight to 93.1% 
(± 0.9%, 5%-95% confidence). To definitively assess whether a resistant SET2 
clone existed in this model, SET2 cells were exposed to 2 days of ADCC with 
E:T 50:1. The reaction was then quenched by killing the effector cells with 
puromycin (to which the SET2 target cells were made resistant). The 
remaining cells then underwent a second 18 hour ADCC with E:T 50:1, and 
results were compared to SET2 with PBMCs without ESKM. The pre-treated 
SET2 cells remained susceptible to ADCC with 97.8% cytotoxicity, and no 
evidence of target loss (Figure 4.7C). These results make treatment escape 
via selection and outgrowth of an intrinsically resistant SET2 clone very 
unlikely. Rather, a kinetic escape mechanism is strongly suggested. 
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Figure 4.7. Lack of outgrowth of resistant SET2 cells in vitro. Error bars: 5th to 
95th percentile. A. 3 day ADCC: daily cytotoxicity as measured by flow 
cytometry. Effector to target ratio set at 25:1, with normal donor PBMCs used 
as effectors. Cytotoxicity measured as ratio of live SET2 cells with:without 
ESKM in media. B. Median HLA-A*02:01 cell surface expression of cells in (a) 
on days 1-3 of ADCC by flow cytometry. HLA-A*02:01 increases in cells 
exposed to PBMC with ESKM compared to SET2 cells with PBMC without 
ESKM likely due to inflammatory cytokines. C. Median surface HLA-A*02:01 
expression by flow cytometry of passaged SET2 cells, status-post 2nd round of 
ADCC. 
 
 
Slowing leukemia growth kinetics improved therapeutic efficacy 
 
The evaluation of the kinetic escape hypothesis required the controlled 
slowing of leukemic growth without direct toxicity to the cell. This has been 
previously done in another model by inducing the overexpression of the cyclin-
dependent kinase inhibitor p27Kip1 inducing cell cycle arrest without 
apoptosis30. We transduced SET2 with a doxycycline inducible vector coding 
for CDKN1B gene (coding for p27Kip1 protein). The SET2 p27Kip1 expressing 
cell line (SET2-S) responded to doxycycline mediated induction of p27Kip1 with 
dose dependent growth inhibition (Figure 4.8A-C). In the NSG mouse model, 
ESKM mediated ADCC was dramatically improved by slowing SET2-S growth 
A B C
0
2000
4000
6000
8000
10000
12000
14000
Day 1 Day 2 Day 3
S
E
T
2
 H
L
A
-A
*0
2
:0
1
(f
lo
w
 c
y
to
m
e
tr
y
)
SET2+PBMC SET2+PBMC+ESKM
0
10000
20000
30000
40000
50000
60000
ESKM 
Tx
Control 
(SET2 + 
PBMC)
Control 
(SET2)
S
E
T
2
 H
L
A
-A
*0
2
:0
1
(f
lo
w
 c
y
to
m
e
tr
y
)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Day 1 Day 2 Day 3
P
e
rc
e
n
t 
c
y
to
to
x
ic
it
y
112 
by p27Kip1 overexpression (Figure 4.8D-E). p27Kip1 overexpression alone 
slowed growth but was not therapeutically effective. A comparison of the 
doxycycline treated SET2-S growth in vivo with and without ESKM therapy 
demonstrates that even a modest slowing of leukemic growth results in 
dramatic increase in therapeutic effect (Figure 4.8E). Evaluation of this p27Kip1 
cell line by flow cytometry revealed no down regulation of ESKM binding with 
the overexpression of p27Kip1 (Figure 4.8F). In vitro ADCC performed by 
chromium assay showed minimal differences in ESKM mediated toxicity of 
SET2-S between normal and high p27Kip1 expressing cells (Figure 4.8G). The 
highly improved potency of ADCC/ADCP in these experiments in vivo appears 
to result from slower tumor growth, and therefore supports the hypothesis of 
kinetic escape mechanism of ADCC resistance. 
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Figure 4.8. SET2-S cell evaluation in vitro and in vivo. Error bars: 5th to 95th 
percentile. BLI imaging and growth curves use exponential scale. A. Western 
blot evaluating the protein expression of p27Kip1 measured using a FLAG 
specific antibody. B. Dose dependent growth inhibition of SET2-S cells in vitro 
with increasing doxycycline concentrations. C. Competition assay 
demonstrating decrease in population of SET2-S cells when compared to 
SET2 cells. SET2 and SET2-S cells were mixed 50:50 at t=0 hrs and 2 µg/ml 
doxycycline was added to the media. Expression of tdTomato, marking SET-S 
cells, was measured over time. D. BLI at the end of 3 weeks of therapy in NSG 
mouse model of SET2-S leukemia (day 28 status-post leukemic injection). 
Controls had injections of SET2-S cells and no therapy. ESKM treated mice 
received the antibody only on day 6 onwards. The other two groups got 
doxycycline alone or doxycycline with ESKM. E. A plot on log scale of the mice 
treated in panel D over one month. SET2-S in vivo growth, by BLI, evaluating 
ESKM ADCC with and without p27Kip1 overexpression, demonstrating clear 
superiority of ADCC treatment on slower growing SET2-S cells compared to 
wild type controls. F. Flow cytometry of SET2-S cells with and without 
doxycycline exposure, evaluating ESKM binding. G. ADCC of SET2-S with 
and without upregulation of p27Kip1, activated by doxycycline exposure. The 
overexpression of p27Kip1 appears to stabilize SET2-S, decreasing the 
chromium release of both control and ESKM treated cells. 
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DISCUSSION 
Antibody therapies are effective at targeting tumor specific antigens, 
modulating the immune system to increase immune cell mediated killing of 
tumor cells, or by blockade of oncogenic signaling pathways. One limitation of 
targeting tumor antigens is lack of therapeutic efficacy as a single agent 
modality. Other than mAbs that mediate the up-regulation of T-cell activity via 
checkpoint blockade, a mechanism of action completely independent of 
ADCC, most native mAb alone do not result in complete remissions or long-
term survivals. Even more complex constructs, such as brentuximab vedontin, 
are used in combination or sequenced with chemotherapy(173). Other 
effective mAb, such as rituximab and trastuzumab, rely on additional 
mechanisms of action such as signaling blockade to inhibit cellular 
proliferation(174). The lack of mAb ADCC/ADCP potency is a significant 
limitation for this class of drugs, given the ability to specifically target a large 
number of new antigens. While combining antibody therapy with 
chemotherapy has improved outcomes, these two treatments may not 
synergize well in many instances, since chemotherapeutic agents can be 
naturally toxic to the effector cells required for ADCC. 
ESKM as a therapy for BCR-Abl resistant ALL 
ESKM is a potent mAb therapy that is not susceptible to tumor escape 
by gatekeeper mutations in the Abl domain, a known clinical mechanism of 
resistance to TKI targeting the BCR-Abl fusion (171). ESKM is also a 
therapeutically effective antibody in mouse models of other human leukemias 
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and solid tumors(128, 130). However, as monotherapy, the antibody was 
unable to achieve cures in these models. In combination, TKIs and ESKM did 
not exhibit enhanced toxicity, had at least an additive therapeutic effect and 
resulted in molecular cures of Ph+ ALL in mice. BM relapse of leukemia post 
treatment may reflect inadequate effector cells rather than loss of antigen, or 
local stromal cell protection, since RMF/HLA-A*02:01 was still expressed on 
leukemia cells at the end of therapy and reducing leukemic cell adherence to 
stromal cells with plerixafor did not significantly increase antileukemic activity.  
The data support a more generally accepted hypothesis that mAb 
therapies would likely benefit from combination therapy to decrease cancer 
burden and keep cancer growth rates low, thereby fostering more effective 
ADCC in vivo at increased E:T ratios. Thus, patients with CML in remission on 
TKIs may be ideal candidates for ESKM treatment, since they have minimal 
residual leukemic burden and slow cancer growth. The main mechanism of 
escape of ALL for ESKM monotherapy seemed to be inadequate effector 
function, as target down-regulation and intrinsic resistance to ESKM mediated 
ADCC was not observed.  
An important advantage to TCRm antibody therapy was its efficacy 
against pan-resistant Ph+ leukemias. First and second generation TKI’s are 
not effective against leukemias that carry the BCR-ABL T315I resistance 
mutation. Such mutations occur in 12-15% of screened patients with CML and 
are a source of relapse and failure of treatment(175). While a third generation 
TKI, ponatinib, is effective in the presence of this mutation, its use is currently 
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restricted because of severe vascular toxicity(176). Therefore, there is an 
urgent need for alternative therapies in patients with these mutations. ESKM 
works through an entirely different mechanism than the TKI’s, and our 
experiments demonstrated equal efficacy of the TCRm mediated ADCC 
against both TKI sensitive BV173 and its resistant mutant BV173R in vitro and 
in vivo. Combining ESKM with another TKI could result in faster remissions 
and possible cure, which may allow a shorter course of these expensive, 
potentially toxic and non-curative drugs.  
While these data strongly support the effectiveness of combining TKIs 
with ESKM, there are limitations. The patients must be HLA-A*02+, and have 
leukemias expressing WT1. Leukemias with reduced HLA-A*02 expression 
may be resistant to ESKM. Additionally, low WT1 expression, or inadequate 
concentrations of effector cells such as in a leukemia packed bone marrow, 
may also limit cytotoxic activity of this TCRm antibody. Importantly, despite its 
potent activity against Ph+ ALL, ESKM had no discernable effect on normal 
human BM progenitor cells within these model systems. Because of its 
specificity for the leukemia cells, ESKM should cause minimal toxicity. In 
addition, this antibody could be evaluated in human clinical trials during the 
peri-stem cell transplant time frame. 
 
Resistance to ESKM mediated ADCC in AML 
ESKM relies solely on ADCC for its cytotoxic effect in vitro and in vivo. 
While we have demonstrated efficacy in both ALL and AML models with 
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ESKM, as a single agent durable remission is difficult to achieve. The data 
here are derived from experiments that utilize the antibody ESKMto elucidate 
the in vitro and in vivo factors which result in leukemic escape. The data do 
not support down-regulation of target epitope, inadequate pharmacokinetics of 
the mAb, the inhibition of effector cells, suboptimal effector to target ratio in the 
BM, or the microenvironment as important mechanisms of mAb therapy 
failure. Instead, we observed that growth kinetics of the leukemia, and the 
quality and number of effectors, was critical to leukemic relapse. This was 
demonstrated by the superior efficacy of ESKM in mice on slower growing 
clones of AML cells, which differed from the parental line only by the 
introduction of an inducible cyclin-dependent kinase inhibitor p27Kip1 to slow 
the AML cell cycling time. These results indicate that leukemia may be able to 
evade ADCC and ADCP by outgrowing effectors. These findings are 
especially relevant for the use of mAb in the setting of rapidly growing 
population of leukemia cells, with a limited number of effectors whose activity 
may be suppressed by chemotherapy or the disease itself. For mAb that act 
via other mechanisms not requiring effectors, such as the direct killing 
demonstrated by rituximab or traztuzumab, these issues may be less 
important and may warrant use of cytostatic drugs, by targeting growth 
pathways such as MAPK, in combination with ESKM and other TCRm to yield 
synergy(177, 178). 
The concept of outgrowing antibody mediated destruction in humans 
has been documented in another disease. In idiopathic thrombocytopenia 
119 
purpura (ITP), the antibody mediated destruction of platelets can be treated by 
thrombopoietic agents, which are very effective at increasing platelet numbers 
simply by increasing platelet production(179). The converse therefore is 
feasible, and documented by our data: slowing down target cell growth 
increases susceptibility to the effector mechanisms. Interestingly, the escape 
mechanism does not appear to be simply a matter of inadequate E:T ratios as 
the initiation of therapy at time zero or addition of more effectors, either by 
infusion or cytokine induction, did not prevent relapse.  
These findings may be highly relevant currently, given the rapid 
development and approval of many cellular growth pathway inhibitors, each 
targeting specific overactive signaling pathways in cancer cells, many of which 
are cytostatic. With the ever-increasing ability to detect cell growth drivers and 
an expanding library of small molecules, such as tyrosine kinase inhibitors, 
including BRAF inhibitors, MEK inhibitors, and JAK inhibitors, it will soon be 
possible to slow the growth of many tumor cells safely in vivo. Indeed, we 
showed that in mouse models of Ph+ ALL, ESKM plus imatinib was more than 
additive, and ESKM plus dasatinib was in some cases curative. Combining 
cytostatic therapy with targeted immune therapy, such as mAbs, may therefore 
result in synergistic and possibly curative outcomes without resorting to 
cytotoxic chemotherapy. Furthermore, chemotherapy may contribute to the 
effector cell dysfunction. Of course, chemotherapy may still be required to 
lower tumor burden for more optimal E:T ratios. 
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THESIS SUMMARY 
 
USE OF POOLED shRNA SCREENS TO DISCOVER REGULATORS OF 
MHC-I 
 
We demonstrated the use of a pooled shRNA screen to study 
regulation of the surface molecule MHC-I on tumor cells. This is the first 
comprehensive study of kinases which regulate surface levels of MHC-I on 
tumor cells. Using a hypothesis driven screen is a useful starting point for 
discovering regulation of a pathway. We hypothesized that kinases, which are 
involved in dysregulating oncogenic signaling, would influence surface levels 
of MHC-I. Interferon gamma, a known pharmacologic regulation of MHC-I, 
works through signaling of the JAK-STAT kinase pathway, so it is not 
surprising that other kinases are involved in the regulation.  
MEK and EGFR were validated as regulators of MHC-I in tumor cells. 
MEK has been demonstrated to regulate MHC-I in gastric cancer, and 
melanoma. We validated these data in our mesothelioma cell lines and also 
broad tumor types, ranging from melanoma, NSCLC, thyroid cancer, colorectal 
cancer, and pancreatic cancer. Given that immunotherapies are being 
evaluated for many, if not all of these neoplasms regulating antigen 
presentation may be a beneficial strategy to increasing therapeutic efficacy.  
Future directions 
The use of a pooled shRNA screen, coupled with FACS and next 
generation sequencing to deconvolute shRNA construct identity and 
abundance is a novel concept that could be applied broadly to other surface 
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antigen targets, and potentially any protein with a specific antibody compatibly 
with flow cytometric based assays. One could envision looking at regulation of 
checkpoint inhibitors such as PD-L1 using a screen similar to this one, or for 
looking at genes affected phosphorylation of ERK.  
Utilizing a similar screening platform, this could be done with CRISPR 
based knockout of genes, which may lead to more potent phenotypes than 
what was seen with shRNA based loss of function screens. In some cases, 
complete knockout is required for a phenotype to be observed, and this 
screening strategy would be amenable to CRISPR based lentiviral pooled 
screens (180). Gain of function screens using ORF based libraries could also 
be used if FACS based screens(181).  
 
THE MAPK PATHWAY REGULATIONS MHC-I 
 
The MAPK pathway is responsible for growth, proliferation, gene 
expression, and differentiation of many tissues. This pathway is often activated 
in cancers, and is part of the oncogenic process. We discovered two hits in our 
screen which are part of the MAPK pathway, EGFR and MEK, as negative 
regulators of MHC-I. Inhibition of these kinases, either by shRNA or by specific 
small molecule inhibition led to increased surface MHC-I.  
EGFR is a receptor tyrosine kinase which is often constitutively 
activated in various cancers, such as NSCLC via mutations in the tyrosine 
kinase domain or via overexpression in colorectal cancer and others (182, 
183). EGFR signals downstream into PI3K, MAPK, and STAT, leading to 
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broad effects on angiogenesis, motility, survival, proliferation, and 
differentiation (184).  
We demonstrated that EGFR is a potent regulator of surface MHC-I in 
tumors with activated signaling due to activating EGFR mutations. Knockdown 
of EGFR with shRNA led to an increase in surface MHC-I. We further 
phenocopied this effect using specific small molecule inhibitors, either erlotinib 
or afatanib. We were able to increase tumor antigen presentation by 
measuring WT1 tumor antigen presentation with ESKM upon treatment of a 
mesothelioma cell line. EGFRi in NSCLC cell lines with activating EGFR 
mutations led to increased levels of HLAA, TAP1, TAP2, and B2M, which are 
key components of MHC-I and antigen presentation machinery. We also 
observed dose dependent increases in HLAA and B2M with increasing EGFRi.  
MAP2K1 or MEK was also validated as a regulator of MHC-I. Work 
previously has demonstrated the role of MEK in regulating gastric cancer 
MHC-I. MEK was identified in our unbiased kinome screen as well to regulated 
MHC-I expression in mesothelioma, and we were able to further validate these 
effects in broad tumor types such as melanoma, colorectal cancer, pancreatic 
cancer, and thyroid cancer cell lines. Given that many cancers have activation 
of the MAPK pathway, and immunotherapy is being evaluated in many of 
these same cancers it may be relevant to consider regulating antigen 
presentation and MHC-I expression in addition to treatment with an 
immunomodulatory drug(79, 185).  
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Future directions 
 The work described here sets up a framework for evaluation of kinase 
targets that are commonly activated via mutations, amplifications, deletions, or 
autocrine signaling to be utilized as targets in up-regulation of MHC-I and 
tumor antigen presentation. In particular, many kinases are known to feed into 
the MAPK pathway, identified as a key regulator in tumor cells of MHC-I 
expression. While we focused on EGFR and MEK, other kinases have been 
shown to feed into the MAPK pathway. We have some preliminary data on 
RET regulating MHC-I. Other RTK such as ALK, overexpressed in certain 
NSCLC tumors, and MET, amplified also in NSCLC and hepatocellular 
carcinoma, are therapeutic targets that could also be evaluated for their role 
on regulating MHC-I.  
 Discovering the downstream effectors that regulate MHC-I, along with 
components of the antigen presentation machinery would also be of interest. 
We have data suggesting a role for STAT1, and this could be followed up 
mechanistically with CHiP experiments to definitively show the role of STAT1 
in regulating MHC-I upon MAPK inhibition. The regulation of MHC-I may also 
depend on where the activated signaling originates from, as RTK may signal 
to a different set of pathways than a downstream BRAF mutation. This may 
also be relevant in predicting the response to MAPKi in regulating MHC-I.  
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USE OF KINASE INHIBITION IN COMBINATION WITH IMMUNOTHERAPY 
FOR SUPERIOR THERAPUETIC EFFICACY 
 
Kinase inhibitors have been utilized for over two decades now as FDA 
approved therapies for cancer, starting with the approval of imatinib for CML 
with BCR-Abl translocations. Since then, many cancers have been 
appreciated to have presence of genetic, epigenetic, or autocrine/paracrine 
dysregulation leading to chronic signaling of oncogenic pathways. Blocking 
cancer cells from their addiction to oncogenic signaling has demonstrated to 
have therapeutic efficacy in many cancers(186).  
 While the mechanisms of various immunotherapies are being fully 
worked out, it is understood that antigen presentation on MHC-I plays an 
important and vital role in the response to immunotherapy. Mutational burden, 
leading to robust neo-antigen presentation on MHC-I has been shown to be 
predictive of response to immunotherapy (107, 108). We propose that limited 
presentation of these antigens may lead to ineffective response to various 
immunotherapies dependent on antigen presentation.  
 By utilizing inhibition of two well characterized targets, EGFR and MEK, 
to up-regulate MHC-I this provides for a rational combination therapy which 
targets tumor growth and also antigen presentation to the immune system. We 
demonstrated that use of MEKi can increase two forms of immunotherapy, 
using TCRm antibodies in combination with trametinib, or with p-mel specific 
T-cells against a murine melanoma treated with MEKi. Others have shown that 
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it is possible to combine MEKi with CTLA-4 and PD-1 checkpoint blockade in 
syngeneic mouse tumor models (110, 111, 113).  
 Further models to demonstrate the use of EGFRi in combination with 
immunotherapy are warranted. We did not have a model in place to ideally 
evaluate this, but use of genetically engineered mouse models with transgenic 
expression of EGFR mutations serve as an ideal platform to evaluate 
combination with PD-1 therapy. Others have published on increased PD-L1 
and PD-1 expression in the tumor of transgenic EGFR mutant lung 
adenocarcinoma mouse models, and we also examined the data and showed 
decreased levels of MHC-I and antigen presentation components (101). This 
could set up a model by which tumors, through EGFR signaling, would 
activate PD-L1 expression on tumors and down-regulate MHC-I and antigen 
presentation machinery such as TAP1 and TAP2 to allow for immune escape 
and sustained proliferation of the tumor. Our data support this model, and we 
expect that combined blockade of PD-1 along with EGFRi to be 
complementary therapies.  
 These data support a model by which inhibiting constitutively activated 
kinases that feed into the MAPK pathway, such as EGFR and MEK, or other 
kinases whereby constitutive activation has been demonstrated to play a role 
in the MAPK pathway could be treated with specific small molecule inhibitors 
to increase immunogenicity of the tumor. This would also be compatible with 
use of an immunotherapy dependent on antigen presentation, such as 
checkpoint blockade, vaccination, adoptive T-cell therapy, or TCRm mAb. This 
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may argue for upfront use of combined kinase inhibition with immunotherapy 
versus using agents sequentially after a patient has failed therapy with one 
treatment.  
Future directions 
The work described here sets up an ideal set of in vivo combination therapies 
to evaluate. We have tried work with ESKM in combination with MEKi but have 
not seen synergy that was observed in vitro. Off target effects on activation 
and proliferation of leukocytes has been seen with MEKi, which act as the 
main effector for ESKM (110, 114, 187). Optimal dosing schedules will be 
required in order to properly sequence this with immunotherapy.  
 EGFRi may be a more attractive target for immunotherapy 
combinations, since this has not been seen to affect immune effector cells. 
Utilizing a transgenic EGFRm mouse model, we could evaluate combinations 
of EGFRi with anti PD-1/PD-L1 therapies. One issue is that the transgenic 
models respond exquisitely well to monotherapy EGFRi, leaving a very small 
window for effective combination (90). Another approach is use of humanized 
mouse models, which have been shown to be useful for preclinical 
immunotherapy studies such as anti-CTLA4 and anti-PD1/PD-L1 with human 
tumors in murine models. We plan to evaluate use of EGFRm human NSCLC 
in humanized mice for combination therapy with EGFRi and anti PD-1 therapy 
with pembrolizumab.  
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STRUCTURE OF A TCR MIMIC ANTIBODY WITH TARGET PREDICTS 
PHARMACOGENETICS AND POTENTIAL OFF TARGETS 
 
Use of a TCR mimic against the oncoprotein WT1 has demonstrated 
potent in vitro and in vivo efficacy. We have examined the sequence specificity 
of ESK previously, but have never completely understood the determinants for 
specificity and binding. Utilizing an x-ray crystal structure of ESK in complex 
with HLA*A02 and the WT1 derived peptide target RMFPNAPYL we have 
gained insight into the basis of ESKM on target binding and affinity. We also 
learned of the broaded of potential haplotypes of HLA*A02 which ESK is 
compatible with, a unique property of this TCRm.  
ESK was found to bind in a manner differently than how TCR bind to 
the HLA molecule. ESK contacts both the HLA molecule and the RMF peptide, 
similar to a TCR. The difference is the location of the contacts between the 
ESK fab, which are located over regions rich in Arg residues on the HLA*A02 
molecule and RMF peptide. ESK primarily contacts the first 3-4 amino acids of 
the RMF peptide. This is an unusually interesting property, which given the 
counter negative charges on the ESK Fab region may explain the observed 
sub-nanomolar affinity seen with the TCRm, when compared to TCR which 
bind with micromolar affinity, despite both binding with comparable surface 
areas to the HLA*A02 and peptide portions.  
The structure also allowed for explanation of another interesting 
property of ESK, which is the broad binding to various HLA*A02 subtypes, 
such as HLA*A0203, HLA*A0207 and others. This is a unique property of 
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ESK, whereas this is not seen with TCR. This provides a huge advantage to 
use of ESK as a targeting modality for WT1+ HLA*A02 tumors, as there are 
TCR based therapies currently in clinical trials against WT1+ tumors but are 
limited to the specific subtype HLA*A0201(26). Our structural data revealed 
that ESK binds to regions that are conserved amongst the different HLA*A02 
polymorphisms, allowing for subtype universal TCRm. This may argue for 
TCRm based therapies to be utilized in adoptive T-cell and CAR-T cell based 
therapies, allowing for an expanded patient population to benefit from these 
therapies.  
Lastly, we wanted to examine the potential off targets of ESK by 
utilizing a bioinformatics based approach informed by our structural studies. 
By using BLAST and NETMHC algorithms, we were able to identify some 
potential off target peptides of ESK, derived from two genes, MED13L and 
PIGQ. These were confirmed to bind to the HLA*A02 molecule and were 
conducive to ESK binding at similar levels to what is seen with RMF binding. 
While it has been demonstrated that ESK did bind a small subset of normal 
human B-cells, it is uncertain what non WT1 target was contributing to the 
binding. This data suggests these proteins, amongst other potential off targets, 
may contribute to the off target binding of ESK. This has the potential to 
influence how off targets of TCR and TCRm based therapies are evaluated.  
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Future directions 
The structure of ESK1 in complex with the target WT1 peptide and HLA*A02 
can be utilized for future development of more specific TCRm mAb to avoid 
biasing in binding that leave open opportunities for off target peptides to be 
bound and potentially elicit killing by effector cells. We already have utilized 
the structural information to develop second generation versions of ESK, 
which bind closer to the orientation which TCR bind to pMHC complexes and 
have in preliminary experiments demonstrated higher specificity for WT1+ 
cells. Utilizing better screening strategies, we can develop more specific, 
potent therapeutic TCRm for immunotherapy.  
 
IDENTIFYING AND BYPASSING RESISTANCE TO ESKM IN ACUTE 
LEUKEMIA 
 
 ESKM is an ideal therapy to target WT1+ acute leukemias, which 
currently only have one FDA approved biologic therapy, blinotinumab for 
CD19+ ALL. We propose that targeting WT1+ leukemias is a viable 
therapeutic strategy. Previous work demonstrated efficacy of ESK1 in acute 
leukemia in vitro and in vivo(50). We went on further to show that in BCR-Abl 
positive ALL, ESKM could be used in combination with TKI targeting BCR-Abl 
in WT1+ leukemias. Interestingly, ESKM was more potent that first generation 
imatanib in BCR-Abl+ ALL. We also showed that combination with the more 
potent dasatinib, in combination with ESKM, could result in curative strategies 
in ALL. 
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 We also demonstrated that in nearly pan resistant BCR-Abl with T315I 
gatekeeper mutation in ALL, ESKM was still an effective therapy. Superior 
therapy was also seen by combining ESKM with ponatinib, the only FDA 
approved TKI therapy for T315I mutated BCR-Abl. Given the life threatening  
toxicity seen with ponatinib, leading to its temporary withdrawal as an FDA 
approved drug, we believe that ESKM may be a complementary therapy for 
use in T315I ALL and CML, which may have minimal side effects as seen in 
preclinical toxicity studies(130, 176).  
 While we had seen some efficacy with ESKM in AML, the therapy was 
inferior to what was seen in ALL despite tumors having similar levels of 
binding and killing of ESKM. Another issue for AML is the lack of targeted 
therapies approved for AML, with the exception being ATRA in PML-RARA 
translocated AML.  
 Using xenograft mouse models of AML cell line SET2 in NSG mice, we 
evaluated potential mechanisms of resistance to ESKM in vivo. Target down-
regulation was not observed. Nor was intrinsic resistance to ADCC, the 
predominant mechanism by which ESKM works in vivo. We evaluated 
insufficient effector cells by engrafting fewer leukemia cells, thereby increasing 
the effector to target ratio. The leukemia was still able to growout of 
continuous ESKM therapy. Drug penetrance into tumor was not observed as a 
limitation.  
We hypothesized a kinetic mechanism by which ESKM is unable to kill 
at a fast enough rate. This was demonstrated by slowing down the kinetics of 
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SET2 by overexpression of a cell cycle blocking protein, p27kip, which led to 
slower cell cycling but not apoptosis. Overexpression of p27kip did not lead to 
alterations in binding of ESKM or more sensitivity to ADCC. In vivo, 
overexpression of p27kip in combination with ESKM led to a greater than 
additive effect in leukemia growth inhibition when compared to either 
overexpression alone, or ESKM treatment alone.  
The kinetics of leukemia growth leading to sensitivity to an antibody 
therapy depedent on ADCC may have broad implication for trial design. This 
may indicate that ESKM for AML should be paired with leukemias that are 
being treated with cytostatic therapies. While overexpression of p27kip is not 
physiologic, it has been shown that hypomethylating agents such as 
decitabine and azacytadine can lead to increased levels of p27kip(188). We 
expect that more targeted therapies such as FLT3 inhibitors will become 
available for use in leukemia and may by ideal candidates for combination 
therapy with TCRm mAb such as ESKM.  
 
Future directions 
The data shown for ESKM has demonstrated that kinetics plays a role in 
outgrowth and resistance by leukemia. We are interested to see if this applies 
to other TCRm, and other antibodies. While other antibodies have multiple 
mechanisms of action, such as direct killing by signal blockade or induction of 
apoptosis, ADCC remains an important mainstay of therapeutic activity of 
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mAb. This may also be relevant to antibody therapies that target much lower 
epitope densities 
 Other mechanisms besides slowing down tumor growth could include 
boosting the ability for effector cells to kill target cells. We have preliminary 
data on use of CD47 antagonists that increase efficacy of multiple TCRm in 
vitro and in vivo by promoting antibody dependent cellular phagocytosis, a 
major form of killing utilized by macrophages.  
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